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Osteoarthritis (OA) is the most common arthritic disorder and a leading cause 
of musculoskeletal disability. The most commonly affected joints in OA are the 
spine, hip, knee and hand joints (Brandt et al., 2003). OA is estimated to affect 
almost 40% of subjects over the age of 70 (Lawrence et al., 2008). The 
economic burden of arthritis is estimated to be 1−2.5% of the gross national 
product in the Western world (Bitton, 2009). The ageing of the population, 
rising problem of obesity and lack of definitive treatment for the prevention of 
the disease, or reducing its progression, ensure that the impact of OA on public 
health will continuously increase.  
Epidemiological studies have demonstrated that OA is a complex disorder 
with a large number of environmental and genetic risk factors (Figure 1). 
Genetic factors have been shown to influence the dynamics and outcomes of 
OA at various stages of the disease, as have other OA risk factors, such as 
obesity, skeletal shape, bone mass and synovial inflammation (Valdes et al., 
2011a). The general purpose of genetic research in the OA field is 1) to identify 
underlying causative genes and pathways, and increase the understanding of 
molecular mechanisms of the disease, with potential implications for novel 
therapeutic approaches, and 2) increasing the ability to predict the risk of the 
disease through identification of risk geno- and haplotypes (van Meurs et al., 
2012). 
In OA, the knee is the most significant clinically affected site (Peat et al., 
2001; Figure 2). In fact, since 2002 the genetic pattern of knee OA (KOA) has 
been investigated by genome-wide linkage analysis, numerous associated 
studies of candidate genes have been performed, and several genes are now 
known to be consistently associated with the risk of KOA (Valdes et al., 2011a). 
However, considerable progress still needs to be achieved in the understanding 
of the pathogenic OA pathways associated with genetic susceptibility. The 
identification of novel unknown members and the elucidating of the 
mechanisms of OA susceptibility genes are possible through functional genomic 
research into affected joint tissue (Meulenbelt, 2011). Moreover, the complex 
consideration of promising candidate genes on the mRNA and protein levels, in 
cartilage and other joint tissues, could significantly improve the current 
knowledge of disease pathogenesis and even provide hypotheses for novel 
treatment research in OA fields. 
The identification of a novel gene associated with OA risk is challenging due 
to the large amount of heterogeneity within the clinical subset of the disease, 
heterogeneity between different ethnic groups and the appearance of small 
effects of OA at many loci, requiring a large number of study participants to 
establish genetic risk (Valdes et al., 2011a). Nowadays, there are only a few 
genes that have been shown to have a strong association to OA, and there have 
been many association studies showing undefined significance (Chapman et al., 
2012; Reynard et al., 2012). Of the described novel genes that are potentially 
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implicated in OA pathogenesis, ADAM12 (disintegrin and metalloproteinase 
domain-containing protein 12) and CILP (cartilage intermediate layer protein) 
seems to be promising and little investigated OA contributors. 
ADAM12 is a member of the ADAM family, which belongs to the main 
proteolytic enzymes that regulate extracellular matrix turnover in cartilage 
(Aigner et al., 2006). Several associated studies have implicated ADAM12 as a 
potential OA candidate gene (Valdes et al., 2004; Loughlin, 2005). Moreover, 
an over-expression of ADAM12 mRNA was found in OA cartilage (Okada et 
al., 2008), suggesting disease-associated altered behaviour in OA, at least in 
joint cartilage. However, there is a lack of systematic data on the actual relation 
of ADAM12 to OA genetic risk and its possible OA-associated pathogenetic 
























Figure 1. The complexity and interaction between risk factors involved in osteoarthritis. 
SNP: single nucleotide polymorphism 
 
Another novel promising OA marker is CILP (also known as CILP1). CILP1 is 
an extracellular matrix glycoprotein, which is chiefly expressed in cartilage 
tissue (Lorenzo et al., 1998a). The amount of CILP1 protein increases with the 
ageing of human articular cartilage and up-regulation of CILP expression has 
Systemic risk factors: 
• Age 
• Gender 
• Body mass index 
• Ethnic characteristics 
• Bone density 
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• Malalignment 
• Heavy physical job 
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been described in early and late stages of OA (Lorenzo et al., 2004). However, 
there is increasing evidence that CILP may be produced in non-cartilaginous 
tissue, as well as in cartilage (Cardenal et al., 1996; Bernardo et al., 2011). 
Similarly to ADAM12, there is only limited information on the behaviour of 
CILP in OA-altered tissue other than cartilage. Therefore, the advancement of 
our knowledge of the contribution of these two genes to knee OA 
pathophysiologic processes can provide new insights into disease mechanisms 
and provide direction in the development of new treatment strategies. 
 
A           B        C 
      
 
Figure 2. The structure of knee joints and their radiographic imaging. A) The knee joint 
is composed of three functional compartments: the medial and lateral tibiofemoral 
compartment and patellofemoral compartment. B) X-ray radiographs of the knee (no 
radiographic OA features). C) Radiographic knee OA−presence of osteophytes (OPH) 
and narrowing of joint space (JSN) in the knee joint (courtesy of Department of 




4. REVIEW OF LITERATURE 
4.1. Osteoarthritis (OA) 
4.1.1. OA consensus definition and modern conception 
In the second half of the twentieth century, the definition of OA changed. OA is 
no longer considered to be a degenerative disease of ageing cartilage and a form 
of hypertrophic arthritis. According to new concept, in addition to articular 
cartilage, OA involves all of the tissues of diarthrodial joints, including sub-
condral bone, ligaments, capsules, synovial membrane and periarticular muscles 
(Flores et al., 2003). Therefore, recognizing OA as a whole-joint disease 
emphasises the importance of the evaluation of all tissues of synovial joints in 
the understanding of OA pathogenesis. Moreover, in the past decade the 
concept of OA as a degenerative disease of ageing cartilage has been giving 
way to the concept of OA as a form of arthritis with an inflammatory compo-
nent (Attur et al., 2002). Due to the aneural and avascular nature of cartilage, 
OA seems not to comply with the criteria of the four cardinal signs of Celsius 
(rubor et tumor cum calore et dolor). However, the inflammatory process can 
alternatively be characterized as the release and activation of toxic cellular 
mediators which promote tissue injury (Attur et al., 2002). Therefore, nowadays 
OA is considered to be an inflammatory form of arthritis, with focal synovitis 
and signs of inflammation at the molecular level within joint cartilage (Attur et 
al., 2002; Loeser, 2008).  
 
4.1.2. Main aspects of OA diagnosis: clinical and radiological 
Clinical diagnosis of KOA 
Clinical OA refers to a syndrome of joint pain accompanied by varying degrees 
of functional limitation and reduced quality of life. The classic diagnostic KOA 
criteria were published by the Subcommittee on Osteoarthritis of the American 
College of Rheumatology (ACR) (Altman et al., 1986). According to ACR 
criteria, the diagnosis of KOA relies on knee pain accompanied by the 
following criteria: age over 50 years, stiffness lasting less than 30 minutes, 
crepitus, bony tenderness, bony enlargement, absence of acute inflammation, 
radiographically detected osteophytes and laboratory findings of synovial fluid 
changes, excluding inflammatory arthropathy (Altman et al., 1986). In 2010 the 
European League Against Rheumatism (EULAR) published its recommen-
dations for the diagnosis of KOA (Zhang et al., 2010). They include three main 
symptoms − knee pain, brief morning stiffness, and functional limitation − in 
combination with three indications revealed by physical examination: crepitus, 
restricted movement and bony enlargement. However, the correlation of this 
clinical OA with early radiographic OA features at the individual level is rather 




Traditionally, the standardized radiographic protocols for measuring joint space 
width in the medial tibiofemoral compartment have become accepted for 
measurement of OA-related structural change in the knee joint (Thomas et al., 
1975). The presence and severity of disease typically are determined using the 
Kellgren and Lawrence (K&L) grading system (Kellgren et al., 1963). The main 
limitations of the K&L system involve the invalid interpretation of the 
osteophyte (OPH) status for the classification of the disease, and other invalid 
assumptions by mixing distinct constructs and conflating different OA 
radiographic features (OPH and joint space narrowing) into one scale (Hunter et 
al., 2012). The significance of the detailed evaluation of OA radiographic 
features has been confirmed by genetic (Uitterlinden et al., 2000) and biomarker 
studies (Kraus, 2011). According to modern considerations, OPH and 
narrowing of joint space (JSN) appear to involve different pathways, and 
different pathophysiologic steps. This suggests that these two radiographic 
KOA features should not be consolidated and ideally should be looked at 
individually (Kraus, 2011). 
Because of the inherent limitations of the K&L system, other individual 
grading systems for the various disease features at the different knee compart-
ments have been developed. Nagaosa et al. have offered grading systems which 
meet the requirements of a separate investigation of the appearance of OPH and 
JSN, as well as permitting the evaluation of OA features for tibio- and 
patellofemoral knee joints (Nagaosa et al., 2000). This system provides separate 
instructions for JSN grading in both genders and demonstrates good re-
producibility with other OA atlases (e. g. the atlas of Osteoarthritis Research 
Society International (OARSI) (Nagaosa et al., 2000). 
 
4.1.3. General aspects of the pathogenesis  
of OA as a whole-joint disease 
4.1.3.1. Narrowing of joint space 
Articular cartilage is avascular and aneural connective tissue providing cover 
for the osseous components of the joints and serving as a load-bearing material 
with absorbing impact. 
In OA, alterations in the normal biochemical activity of chondrocytes are 
mostly caused by abnormal biochemical factors (e.g. trauma and repetitive 
mechanical injury) or genetic factors (e.g. the mutation of matrix molecules) 
(Fukui et al., 2001; Goldring et al., 2007). During the early OA stage, the 
anabolic activities in cartilage are up-regulated through an increased synthesis 
of extracellular matrix (ECM) proteins (Martel-Pelletier et al., 2010), which is 
followed by amplified catabolic activity (Goldring et al., 2009; Kapoor et al., 
2010). The catabolic phase is reflected by the increased production of matrix 
metalloproteinases (MMP), aggrecanases, higher expressions of regulatory 
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proteins, transcription factors, and stress and apoptotic markers (Goldring et al., 
2008; Bertrand et al., 2010). The synthesis of metalloproteinase tissue inhibitors 
in the OA joint is decreased, leading to an imbalance between MMPs and their 
inhibitors (Kanyama et al., 2000). Furthermore, chondrocytes produce a large 
number of inflammatory mediators, including cytokines and chemokines, as 
well as reactive oxygen species, which promote OA-associated cartilage 
destruction (Loeser, 2008). All these alterations lead to a progressive loss of 
cartilage, beginning with fibrillation of the superficial zone and followed by 
matrix loss and the development of fissures (Goldring et al., 2010).  
 
4.1.3.2.  Development of osteophytes 
Osteophytosis is one of the main radiographic features of OA and can be a 
source of pain and loss of function. It is unclear whether OPH develop because 
of pathological joint alterations or during physiological remodelling processes 
secondary to joint changes. Human and animal studies have demonstrated that 
OPH formation can occur without cartilage damage, suggesting that osteo-
phytosis can be triggered in the undamaged joint as a result of mechanical 
stimuli or ageing (van der Kraan et al., 2007). In OA, cartilage damage 
confirmed by JSN is reported to be highly associated with the presence of OPH 
(Boegard et al., 1998a). 
Mesenchymal stem cells (MSC) present in the periosteum or synovium are 
thought to be the precursors of OPH (Shirasawa et al., 2006), suggesting that 
activated synovium can contribute to OPH formation. In addition to MSC in the 
periostium and synovial membrane, macrophage-like cells also contribute to 
OPH formation (van der Kraan et al., 2007). The growth factors produced by 
synovial macrophages seem to be a major factor in this process (Blom et al., 
2004; van Lent et al., 2004). Of those, the most potent factor appears to be 
transforming growth factor beta (TGF-β), which has been shown to be 
extensively expressed by human OPH (Uchino et al., 2000). Additionally, 
insulin-like growth factor 1 (IGF-1) has been shown to be involved in the 
development of OPH (van der Kraan et al., 2007). Therefore, in osteoarthrotic 
joints, the formation of OPH and degradation of articular cartilage represent two 
different processes characterized by various pathophysiological mechanisms, 
triggers, metabolic activity and many undiscovered factors. The investigation of 
both processes as separate mechanisms and the elaboration of novel agents 
involved in OA pathophysiological pathways will expand our current 
knowledge and help to resolve several unclear aspects of OA pathology. 
 
4.1.3.3. Synovitis in OA 
Over the past decade, more attention has been paid to the importance of 
synovial inflammation in OA. Historically OA was traditionally considered a 
non-inflammatory arthropathy due to the relatively low count of neutrophils in 
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the synovial fluid and the absence of systemic signs of inflammation (Wenham 
et al., 2010). Currently, the re-interpretation of OA as a whole-joint disease 
provides greater interest in understanding the pathophysiological role of 
synovial membrane inflammation in OA development. 
In OA, chondrocyte and synovial cells become activated due to exposure to 
environmental events, such as mechanical stress, inflammatory cytokines, and 
altered organization of matrix proteins, including degradation products 
(Heinegård et al., 2011). The synoviocytes produce a large number of 
inflammatory cytokines, chemokines and other inflammatory mediators (e.g. 
tumor necrosis factor alpha, interleukin (IL)-1β, IL-6 and IL-8), which diffuse 
into the synovial fluid and act on the cartilage matrix to promote cartilage 
destruction (Golgring et al., 2011). It is clear that in the affected OA joint a 
vicious positive feedback loop takes place, involving cartilage breakdown and 
synovial inflammation. 
Synovitis is often considered to be a major factor associated with the risk of 
the progression of cartilage loss and signs and symptoms of disease, including 
joint pain, swelling and stiffness (Sellam et al., 2010). The pathological features 
of synovial inflammation are found in at least half of the patients with OA, in 
both early and late OA (Ayral et al., 2005), being more aggressive in early OA 
(Benito et al., 2005).  
Histologically, OA-associated synovia changes demonstrate chronic 
synovitis features (Ayral et al., 2005). Four patterns of OA-associated synovial 
changes have been described: (1) hyperplastic, (2) fibrotic, (3) detritus-rich, and 
(4) inflammatory (Oehler et al., 2002). The hypertrophic pattern (synovial lining 
and villous hyperplasia) has been predominantly diagnosed in patients with 
early knee OA, and the inflammatory pattern has been observed equally in both 
early and late OA (Oehler et al., 2002). The detritus-rich (macromolecular 
cartilage and bone debris) and fibrotic (capsular fibrosis) patterns have most 
often been observed in patients with late-stage disease (Oehler et al., 2002).  
Indeed, synovial fibrosis is often seen in the end stage of the disease (Revell 
et al., 1998). In OA the fibrosis of synovial membrane can be characterized as 
an abnormal healing process with excessive deposition of extracellular matrix 
proteins, resulting in the alteration of the structure and remodelling of synovia. 
Fibrogenesis is a response to a variety of insults, such as inflammation, trauma 
and infection, resulting in an inflammatory reaction (Bastiaansen-Jenniskens et 
al., 2013). Blood monocytes and tissue macrophages, rapidly recruited into 
fibrotic tissue, are an important source of fibrotic cytokines (Gharaee-Kermani 
et al., 2001), of which TGF-β seems to be the most potent (Gruel et al., 2009). 
The latter, along with other functions, recruit fibroblasts to the site of an injury 
and stimulate them to proliferate (Gharaee-Kermani et al., 2001). Fibrosis in the 
OA joint seems to be an important contributor to joint stiffness and a source of 
pain (Hill et al., 2007). Thus synovial fibrosis and synovial inflammation 
represent good targets for improvement in current OA treatment strategies and 
the relief of pain.  
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Therefore, inflammation of synovial membrane cannot be ignored as an 
important factor associated with OA clinical symptoms and disease progression. 
Nevertheless, even today, the role of synovitis is often overlooked. There are 
multiple pathways and mediators that can directly contribute to the development 
and persistence of synovitis, whose molecular pattern is currently under-
investigated. Further efforts to understand the molecular variability of 
mechanisms associated with OA synovitis will help to provide insight into the 
nature of the disease and its heterogeneity. 
 
4.1.3.4. Biochemical markers in OA 
Despite the focus in recent years on the development of OA imaging, the 
identification of patients at risk for incident early disease or disease progression 
remains challenging. Therefore, there is still a need for the development of 
biochemical markers that have the potential for the early identification of 
impaired articular tissue metabolism (e.g. matrix degradation), and that can lead 
to earlier treatment to prevent cartilage and bone degradation. Metabolic 
changes in OA involve all joint tissues, as well as different pathophysiological 
pathways, and therefore are most adequately reflected by complex biomarker 
assays. In terms of the investigation of new players in OA, investigative 
markers should be evaluated simultaneously with biomarkers, reflecting the 
metabolism of different joint tissues, for further understanding of OA patho-
physiologic steps. 
In the past decade, a large number of possible OA biomarkers have been 
studied, and several of them have demonstrated promising results for potential 
diagnostic and predictive purposes in the OA field. One of the most extensively 
investigated biomarkers is a fragment of carboxy-terminal telopeptide of type II 
collagen (CTX-II). The collagen type II is the major part of the articular 
extracellular matrix. CTX-II reflects the intensity of collagen II degradation by 
proteolytic enzymes, such as MMP, collagenases and cysteine proteases 
(Yasuda et al., 2005; Burrage et al., 2006). Owing to its small size, it is freely 
filtered by the renal system and concentrated and measured in the urine (Elsaid 
et al., 2006). Urinary CTX-II (u-CTX-II) correlates well with progressive JSN, 
as well as with osteophytosis, and reflects the burden of disease as well has 
prognostic, efficacy of intervention and diagnosic value (Kraus, 2011). 
The molecular markers of bone turnover have been significantly less studied 
than cartilage markers. Degradation of type I collagen, which is a major 
collagen in bone during subchondral bone resorption, can be detected by 
increased levels of N- and C-terminal cross-linked telopeptides (NTX-I and 
CTX-I) (Garnero, 2007). Of the markers reflecting bone synthesis, a greater 
diagnostic value has been suggested for the amino-terminal peptide of type I 
procollagen (PINP) (von der Mark, 1999). Recent data have confirmed that 
PINP has diagnostic value for progressive osteophytosis and predictive value 
for extensive OA progression (Kumm et al., 2013). 
5  
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4.1.4. Systemic risk factors 
OA is a multi-factor disorder, in whose development the complexity of systemic 
risk factors plays a crucial role. Therefore, in research in the OA field attention 
must be paid to all OA risk factors as important covariates. 
 
4.1.4.1. Age, gender and body weight 
Age 
Age is recognized as a strong OA risk factor. An increase in OA incidence and 
prevalence has been reported for all joints in the elderly population (Felson et 
al., 2000; Lawrence et al., 2008). The biological changes associated with ageing 
seem to contribute to an imbalance between catabolic and anabolic activity in 
the joint. According to published data, older chondrocytes are characterized by 
a loss in normal mitogenic activity and respond poorly to growth factor 
stimulation, as they are unable to maintain homeostasis in the articular cartilage 
(Guerne et al., 1995; Shane Anderson et al., 2010). 
 
Gender 
Women are more likely to suffer from OA than men, and also in more severe 
forms (Srikanth et al., 2005). Genetic association studies have reported gender-
dependent differences in susceptibility to OA (Valdes et al., 2004; Valdes et al., 
2006), and several epidemiological studies have shown sex-specific differences 
in both prevalence and severity of disease (Felson et al., 1998; Richette et al., 
2003). Therefore, there is evidence that innate sex-specific differences may 
exist at the molecular level that contribute to disease severity. A clear increase 
in OA in women during menopause suggests that hormonal factors may play a 
role in the development of OA.  
 
Body weight 
Obesity is a well-known risk factor for OA development in such weight-bearing 
joints as knees and hips. Numerous studies have demonstrated a strong 
connection between obesity-associated joint overload and OA, being first 
reported by Fletcher (Fletcher et al., 1945). Mechanical overload seems to 
activate chondrocytes and accelerate cartilage degeneration (Sellam et al., 
2012). Additionally, an increase in body mass index (BMI) has a negative effect 
on muscle strength, balance and gait (Messier, 2010), which can also contribute 






4.1.4.2. The role of genetic factors in OA development 
4.1.4.2.1. Heritability of OA and genetic studies 
OA has a complex pathology, with numerous environmental and genetic risk 
factors. Generally, OA is thought to be caused by a complex interaction 
between environmental and genetic factors (Valdes et al., 2009). A variety of 
epidemiological studies have demonstrated that genetic susceptibility is a key 
regulator of OA aetiology (Peach et al., 2005). Genetic variations may influence 
several OA risk factors, including obesity, skeletal shape, bone mass and 
synovitis (Valdes et al., 2011a). Furthermore, it has been shown that generalized 
OA phenotype, sensitivity to pain and disease progression may be also 
determined by genetic susceptibility (Valdes et al., 2010a; van Meurs et al., 
2009; Kerkhof et al., 2010). 
In the 1940s familial clustering of OA was first formally studied by Stecher, 
who performed a study of Heberden’s nodes of the fingers within affected 
families (Stecher et al., 1941). Later, OA inheritance has been reported in 
multiple subsequent studies on other common forms of OA affecting the knee 
(Chitnavis et al., 1997; Felson et al., 1998; Hirsch et al., 1998; Neame et al. 
2004), hip (Lindberg et al., 1986, Chitnavis et al., 1997; Lanyon et al., 2000) 
and spine (Bijkerk et al., 1999; Sambrook et al., 1999). According to published 
genetic studies, there is a clear difference between sub-populations of OA and 
different OA phenotypes, such as distinct genetic traits being linked to OA of 
the knee, hands or hip (Madry et al., 2012). For knee OA, in classic twin studies 
heritability has been calculated to be 39% in woman after controlling for other 
OA risk factors, such as age, sex and BMI (Spector et al., 1996). Additionally, a 
magnetic resonance imaging (MRI)-based twin study provided evidence for the 
importance of genetic factors in determining cartilage volume, showing the 
heritability for total knee cartilage volume to be 73% (95% CI 51−85%) 
(Hunter et al., 2003). 
Human genetic studies focusing on the identification of important molecular 
pathways associated with the development of OA pathological changes may 
help to unravel the mechanisms responsible for the appearance of joint damage 
and its progression. OA is generally recognized as a complex multi-factor 
disease that has mostly small and modest effect susceptibility loci (Reynard et 
al., 2012). Over the past decade efforts have been focused on the search for loci 
that predispose to OA. The following approaches most often have been attempts 
to provide insight into the complexity of OA genetics: genetic linkage studies 
(LA), genome-wide association studies (GWAS) and candidate gene studies. 
LA exploits the fact that genes have a tendency to be inherited together 
because they are located close to each other. After identification of a linkage, all 
genes in the linked region need to be identified and in this manner candidate 
genes of interest for a disease can be established. LA has been successful in 
localizing chromosomal regions containing highly penetrant genetic variants. 
However, in a common disease, such as OA, the success of LA is very limited 
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for a number of reasons, including the low power of identification of genes with 
modest effects and the large impact of environmental influences (Risch et al., 
1996).  
After the completion of the Human Genome Sequencing project, which 
provided the opportunity to systematically search across the genome and to test 
large numbers of common genetic variants for association with disease, GWAS 
have been successfully applied to the study of many complex diseases. GWAS 
make it possible to examine the associations of thousands of common genetic 
variants with disease. Recently, two reasonably large GWAS studies for OA 
were published: the Rotterdam and arcOGEN (arc Osteoarthritis Genetics) 
GWAS. Both studies revealed loci with genome-wide significance (p<5x10-8) 
for association with knee and hand OA (Kerkhof et al., 2010), and knee and hip 
OA (arcOgen consortium, 2012). 
While the implementation of GWAS has been highly successful for several 
traits, a number of challenges and problems remain. The acceptable genome-
wide significance level is thresholds below p<5x10-8. The detection of these 
robust signals are possible only with very large sample sizes (thousands of cases 
and controls), or in the case of genetic variants with large size effects, which are 
rather rare in common diseases, such an OA (Chapman et al., 2012). So it is 
very likely that many associations with smaller p-values may in fact also be true 
positives, hidden by their heterogeneity or lack of power. Moreover, there has 
been growing criticism of the huge resources needed for GWAS, and of the 
“missed heritability” problem (Chapman et al., 2012). Thus the combined 
analysis of a large number of studies and international collaboration is a 
possible direction for further OA studies. 
 
4.1.4.2.2. Candidate gene association studies 
Candidate gene association studies are hypothesis-based studies offering a 
relevant approach for the investigation of genetic variations in complex 
diseases. Candidate studies focusing directly on a single gene and frequently on 
functionally significant polymorphisms have played an important role in 
discovering genes involved in complex diseases. The main limitation of 
candidate gene studies is the very small region of the genome under investi-
gation (Chapman et al., 2012). Over the past decade, more than 80 genes have 
been subjected to OA candidate gene association analysis, including genes 
encoding ECM components, genes affecting such bone characteristics as bone 
mineral density, and genes encoding enzymes and catabolic and anabolic 
cytokines (Dai et al., 2010; Valdes et al., 2011a). 
The strongest association with KOA was reported for rs143383 of the 
growth differentiation factor 5 gene (GDF5) in the European population 
(including Estonians) (Valdes et al., 2011b; Table 1). The GDF5 protein is an 
extracellular signaling molecule that is a member of the TGF-β super-family, 
which participates in the development, repair and maintenance of joint tissue, 
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including bone and cartilage (Khan et al., 2007). The rs143383 is one of a 
minority of variants that demonstrate a connection with KOA in different ethnic 
populations (Miyamoto et al., 2007). Moreover, rs143383 is reported as having 
the strongest association with hip OA (Miyamoto et al., 2007), but this relation 
seems to be more controversial than for knee OA. 
Another remarkable association with knee and hip OA in the European 
population (including Estonians) was reported for rs12901499, which is located 
within the first intron of SMAD3 (Valdes et al., 2010b; Table 1). SMAD3 is an 
intracellular protein involved in cell signaling that links the TGF-β signal with 
variations in gene transcription. TGF-β-SMAD3 signaling is essential for 
maintaining articular cartilage; SMAD3 mutant mice homozygous developed 
degenerative joint disease similar to human OA (Yang et al., 2001). However, 
since the association of rs12901499 to OA has been reported only by one 
research, further genetic and functional studies should be performed for 
understanding of its role in OA susceptibility. 
Another gene, encoding TGF-β-interacting–asporin (ASPN), was also re-
ported to be associated with KOA. A variable number of tandem repeats in the 
ASPN gene were associated with decreased TGF-β1-mediated chondrogenesis 
in vitro and were reported to be strongly associated with an increased risk of 
KOA in an Asian population with no overall association in a European cohort 
(Nakumura et al., 2007; Atif et al., 2008; Table 1). Additionally, the importance 
of inflammation in OA pathogenesis confirms a strong association of variants in 
the gene encoding the IL1 receptor antagonist with the severity of KOA (Attur 
et al., 2010; Table 1). 
 
Table 1. List of candidate genes demonstrating the most significant associations with 
knee OA in different populations. 

















(Valdes et al., 
2011b) 
Asp14 in VNTR 
allele 
ASPN 1.95 1.3x10-6 TGF-β signaling  Asian 
(Nakamura et 
al, 2007)  
rs12901499 SMAD3 1.22 7x10-6 TGF-β signaling  European 





IL1Ra 0.15 1x10-4 Inflammation  European 
(Attur et al., 
2010) 
GDF5− growth differentiation factor 5  
ASPN−asporine 
TGF-β−transforming growth factor beta 
IL1Ra−interleukin1 receptor antagonist 
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Furthermore, some smaller studies have suggested the role of genes encoding 
cartilage degradation enzymes and proteases, including disintegrin and 
metalloproteinase domain protein 12 (ADAM12), as well as cartilage glyco-
proteins (CILP), in increased KOA risk (Valdes et al., 2004; Valdes et al., 
2006). Both genes encode multifunctional proteins, which potentially might be 
implemented in molecular pathways associated with OA development.  
The potential contribution of those genes to KOA was described in a British 
cohort (Valdes et al., 2004), but so far there are no data for other European 
regions, including Estonia. Moreover, no meta-analysis involving the elu-




 4.2. ADAM12: characteristics and relation to OA 
4.2.1. ADAM12 biochemical structure and  
association with human diseases 
ADAM12 is a member of the ADAM family, secreted glycoproteins that are 
related to snake venom metalloproteases and matrix metalloproteases. 
ADAM12 is an active metalloproteinase that has cell-binding and cell-signaling 
properties (Kveiborg et al., 2008; for review, see the UniProt and GeneCards 
databases). ADAM12 expression is increased mainly in remodelling and fast 
growing tissue, characterized by cell fusion and growth (Wewer et al., 2005). 
ADAM12 is expressed in most mesenchymal cell types, such as osteoblasts 
(Verrier et al., 2004), chondroblasts (Kveiborg et al., 2006), adipoblasts 
(Kawaguchi et al., 2003) and such fusogenic cells as osteoblasts (Abe et al., 
1999) and placental trophoblasts (Gilpin et al., 1998). Additionally, the 
ADAM12 transcript is found to increase during muscle regeneration in mice, 
suggesting a role of ADAM12 in myogenesis (Bornemann et al., 2000). Some 
studies have indicated that TGF-β is implemented in the transcriptional 
regulation of ADAM12 and is able to induce the expression of ADAM12 in 
several differential pathways (Le Pabic et al., 2003; Le Pabic et al., 2005). 
The human ADAM12 gene contains over 8,800 single nucleotide poly-
morphisms (SNP; NCBI home database) and encodes two alternatively spliced 
transcripts: the long transmembrane protein (ADAM12-L) and the short soluble 
form (ADAM12-S). Both isoforms contain pro, catalytic, disintegrin-like, 
cysteine-rich and epidermal growth factor (EGF)-like domains. The ADAM12-S 
isoform lacks the transmembrane and cytoplasmic domains, but contains a 
unique stretch of 33 amino acids at the C-terminus (Jacobsen et al., 2009; 
Figure 3). 
Both ADAM12 forms (long and short) are active sheddases. ADAM12-L has 
been shown to cleave various pro-forms of membrane-bound growth factors and 
cytokines, such as pro-forms of EGF (Horiuchi et al., 2007), heparin binding 
EGF (Asakura et al., 2002) and the insulin-like growth factor binding protein-5 
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(IGFBP-5) (Okada et al., 2008). Similarly to the long isoform, ADAM12-S also 
mediates the cleavage of IGFBP-3 and -5 (Loechel et al., 2000), suggesting a 
role for ADAM12 in IGF-system regulation during embryonic growth and 
development (Jacobsen et al., 2009).  
The functions of ADAM12, in addition to catalytic events, include cell-
binding activities, which are linked to disintegrin-like, cysteine-rich, and EGF-
like domains. In an in vitro attachment assay, the disintegrin domain of 
ADAM12 binds to integrin, which provides a link between the actin 
cytoskeleton and the extracellular matrix (Eto et al., 2000). The over-expression 
of ADAM12 has been shown to be associated with the induction of the 
reorganization of the actin cytoskeleton, reduced cell adhesion and changes in 
cell survival (Kawaguchi et al., 2003). The cytoplasmic tail of ADAM12-L 
could potentially communicate signals between the intra- and extracellular 
space via the transmembrane domain (Jacobsen et al., 2009). 
Numerous investigations have suggested ADAM12 as an important regulator 
in both the normal development of tissues and a variety of pathological states 
(Wewer et al., 2005), making it a potential drug target. High expression levels 
of both forms of ADAM12 have been observed in several types of carcinomas, 
including breast, liver, gastric, bladder and prostate cancers, as well as 
glioblastomas (for review see Arribas et al., 2006). The possible contribution of 
the ADAM family to cancerogenesis probably can be explained by the 
activation of EGF receptor signaling, via the release of growth factors from the 
cell surface (Kenny et al., 2007; Blobel, 2005). Similarly, both isoforms of 
ADAM12 are highly expressed by trophoblasts during placental growth (Gilpin 
et al., 1998; Ito et al., 2004). Significantly reduced levels of ADAM12 in 
maternal serum have been found to be associated with such chromosomal 
disorders as Down syndrome and Edward syndrome (Laigaard et al., 2003; 
Laigaard et al., 2005a), as well as preeclampsia (Laigaard et al., 2005b), making 
ADAM12-S a potential biomarker of pregnancy abnormality. 
In contrast, the contribution of ADAM12 to inflammatory responses is 
largely unknown. According to recent studies, ADAM12 is up-regulated in the 
interface tissue surrounding implants during inflammatory responses and 
aseptic osteolysis associated with hip replacement implants (Ma et al., 2005). 
ADAM12 levels are also reported to be significantly increased in T-cells 
infiltrating the spinal cord with experimental autoimmune encephalomyelitis in 
mice (Toft-Hansen et al., 2004). Additionally, several studies suggest the 
implementation of ADAM12 in the development of inflammation-induced 




Figure 3. Schematic illustration of human ADAM12 isoforms. The long 
transmembrane ADAM12-L and the alternative shorter ADAM12-S that is released 
from the cell, are both shown as globular molecules with the prodomain noncovalently 
associated with the metalloprotease domain (Kveiborg et al., 2008). 
 
4.2.2. Association studies of ADAM12 gene variants with knee OA 
Several reports have indicated that ADAM12 might also contribute to OA, but 
this relationship has only been sparsely studied. Four single nucleotide 
polymorphisms in ADAM12–rs3740199 (c.142G>C, p.Gly48Arg), rs1871054 
(c.1154+145G>A), rs1278279 (c.1515G >A, p.Asn505Asn), and rs1044122 
(c.2475T>C, p.Ala825Ala)–have so far been investigated in relation to OA in 
the European population (Valdes et al., 2004; Valdes et al., 2006; Limer et al., 
2009). Up to now, the missense variant rs3740199 in the ADAM12 gene was 
reported to be associated with increased risk of OPH development and 
progression in the Chingford study (UK), which included only female subjects 
(Valdes et al., 2004). Later, an extensive GOAL study (UK) was unable to 
replicate this association (Limer et al., 2009); however, the authors of the 
replication study focused on global radiographic KOA and did not perform a 
separate analysis for different KOA radiographic features (JSN and OPH). As 
previously mentioned, OPH and JSN appear to involve different pathways and 
pathophysiologies, and should ideally be looked at individually (Kraus, 2011). 
Therefore, several important associations could hypothetically be missed 
because of a confluenting of radiographic parameters, as well as the lack of a 
separate analysis of both genders. 
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In another British case-control study, the associations between all four 
mentioned ADAM12 SNPs and KOA were insignificant, but one haplotype in 
the ADAM12 gene significantly increased the risk of KOA in men, as well as in 
women (Valdes et al., 2006). However, similarly to the GOAL study, in this 
research no stratification by OA ascertainment criteria was performed. Taken 
together, the impact of ADAM12 on OA pathogenesis remains controversial and 
the possible association should be investigated in more detail and in different 
populations. Moreover, since in the discovery of association signals detailed 
investigation is important, there is a need for systemic research with 
stratification by sex and by KOA radiographic features. 
 
4.2.3. Functional role of ADAM12 in knee OA development 
The identification of compelling genetic associations should be followed by 
functional analyses having a task to assess how the associated alleles modulate 
gene or protein function. In vitro, ADAM12-L is found to be over-expressed in 
OA chondrocytes, and its immunoreactivity correlates with chondrocyte 
proliferation (Okada et al., 2008). Functionally, ADAM12-L may contribute to 
OA-associated chondrocyte proliferation through the mediation of the cleavage 
of IGFBP-5 (Okada et al., 2008). Moreover ADAM12-S has been found to 
stimulate bone growth by modulation of chondrocyte proliferation and 
maturation in murine models (Kveiborg et al., 2006), which support the functional 
importance of ADAM12 in chondrocyte metabolism and, in this way, possibly 
contribute to OA.  
Nevertheless, there are no systematic data reflecting the possible role and 
importance of ADAM12 in OA pathophysiologic processes in different joint 
tissues. No extensive genetic research or studies for elaboration of ADAM12’s 
functional impact in the OA field have been performed. The relation of 
ADAM12 to OA still remains unclear and controversial, and specific pathways 
contributing to OA need to be elucidated. Since separate evaluation either of 
genetic susceptibility or functional consequence have provided only ambiguous 
information, the possible contribution to OA ideally should be investigated 
extensively at the gene, RNA and protein levels. 
 
 4.3. CILP: characteristics and relation to OA 
4.3.1. Biochemical structure of CILP 
Cartilage intermediate layer protein (CILP) is a monomeric glycoprotein of the 
extracellular matrix that plays a role in cartilage scaffolding (Tsuruha et al., 
2001; see for review UniProt and GeneCards databases). There are two 
isoforms of CILP–CILP1 and CILP2–with homology of over 50% (Johnson et 
al., 2003; Figure 4). Both CILPs are post-translationally processed into amino 
(CILP1-1 and CILP2-1) and carboxyl forms (CILP1-2 and CILP2-2) (Johnson 




Figure 4. Schematic representation of CILP1 and CILP2 sequences. CILP1 and CILP2 
demonstrate 50% of homology, sharing trombospondin motif I, Ig type C2 domains and 
furin cleavage sites. The aldehyde dehydrogenase cystein active site is unique to CILP1 
(Johnson et al., 2003). 
 Each of the N-terminal domains of CILP-1 and CILP-2 contains a substantially 
conserved immunoglobulin C-2 type domain and thrombospondin type I repeat 
domain (Johnson et al., 2003; Figure 4). The latter could potentially modulate 
the anchoring ability to other ECM components, including glycosaminoglycans 
and TGF-β1 (Johnson et al., 2003; Barallobre-Barreiro et al., 2012). In vitro 
studies have demonstrated that the N-terminal domain of CILP binds TGF-β1 
directly and antagonizes TGF-β1 in rabbit chondrocytes (Seki et al., 2005). The 
carboxyl-terminal half of CILP1 corresponds to a protein homologous to 
porcine nucleotide pyrophosphohydrolase (NPP) (Lorenzo et al., 1998b) and 
was initially claimed to have an NPP function (Masuda et al., 1997a), but later 
research failed to confirm this enzymatic activity (Johnson et al., 2003; Seki et 
al., 2005).  
 
4.3.2. The association of the CILP gene and protein with knee OA 
Genetic association studies have reported significant associations of the 
rs1561888 (c.-106–412C>T) SNP in the three prime untranslated region  
(3`-UTR) of the CILP gene with radiographic KOA (rKOA) in male subjects 
(Valdes et al., 2006). So far, no replication studies for this variant have been 
performed in European or other populations.  
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The amount of CILP1 protein increases with the ageing of human articular 
cartilage (Lorenzo et al., 1998a; Lorenzo et al., 1998b). Functionally, CILP1 
might play a role in cartilage repair (Lorenzo et al., 1998a). According to 
published data, CILP is important in maintaining cartilage homeostasis in 
humans, and its dysfunction contributes to several diseases affecting cartilage, 
including lumbar disc disease and OA (Seki et al., 2005; Min et al., 2009; Min 
et al., 2010). 
In mice, the injection of recombinant CILP1 has been shown to induce 
arthropathy (Tsuruha et al., 2001; Yao et al., 2004). Moreover, autoantibodies to 
the CILP1 fusion protein have been detected in about one-tenth of the patients 
with OA, suggesting the involvement of CILP1 in the immune-mediated 
process of joint destruction (Tsuruha et al., 2001). In OA cartilage, the 
expression of CILP has been shown to be up-regulated in early and late stages 
of the disease (Lorenzo et al 1998b; Lorenzo et al., 2004), suggesting the 
specificity of CILP1 in OA and providing a basis for considering CILP1 as a 
potential OA biomarker. Currently, there are only limited data on CILP gene 
regulation (Mori et al., 2006), and no functional research has been published 
identifying OA susceptibility pathways; therefore, the impact of CILP in OA 
pathogenesis is currently unclear and data regarding its involvement in specific 
pathophysiological steps are rather limited. 
In fact, CILP1 is produced by chrondrocytes and has been found to be 
specifically expressed in cartilage, localizing in the intermediate layer of 
articular cartilage, but not in the superficial or in the deepest regions (Lorenzo 
et al., 1998a). Additionally, CILP1 has been reported to be abundantly over-
expressed in lumbar disc tissue (Hirose et al., 2002). At present, little is known 
about CILP mRNA and protein expression in non-cartilaginous tissues, but 
there are suggestions that CILP may not be exclusively produced by 
chondrocytes. In particular, CILP1 and CILP2 have been detected in mouse 
connective tissue (Bernardo et al., 2011). Thus, the cartilage-specific origin of 
CILP is currently unclear, suggesting the possibility of production in other 
tissue of the synovial joint. However, the original source and type of cells 
responsible for CILP production in non-cartilaginous tissue is currently 
unknown. Furthermore, similarly to ADAM12, there are no identifiable data on 
CILP mRNA and protein expression pattern, or on the CILP function in 
synovial joint tissues, other than cartilage. Since the evaluation of gene/protein 
expression in different tissue may be able to assess which particular pathways 
are implicated in disease initiation and progression (Reynard et al., 2013), there 
is a need for further survey of CILP in osteoarthrotic joints. The intensive 
investigation of CILP in different tissues of the OA joint might reveal unknown 
aspects of its biological nature, as well as provide insight into the mechanisms 
involved in OA pathophysiological pathways. 
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5. AIMS OF THE STUDY 
To perform an analysis of ADAM12 and CILP genes on DNA−RNA−protein 
levels in radiographic knee osteoarthritis on the basis of an Estonian cohort. 
Specific aims: 
I. To investigate possible associations of selected SNP of ADAM12 
(rs3740199, rs1871054, rs1278279 and rs1044122) and CILP (rs1561888) 
with rKOA. 
II. To investigate the relationship of the serum level of ADAM12 protein with 
the radiographic features of KOA and OA molecular markers. 
III. To investigate the association between histological synovitis, features of 
rKOA and levels of ADAM12 and CILP mRNA in bioptic samples.  
IV. To clarify the possible origin of ADAM12 and CILP1 proteins in the 
synovial tissue and the relationship between the local production of 
























6. PATIENTS AND METHODS 
6.1. Study subjects 
The study consisted of two different study groups: a population-based cohort 
recruited in 2002−2006 from southern Estonia and subjects undergoing 
arthroscopy in Tartu University clinics in 2007−2010. All of the recruited 
subjects participated in in-depth clinical examinations, including inquiry, 
performance tests, X-ray radiography of the knee joints, donating blood samples 
for DNA extraction (dipotassium ethylenediaminetetraacetic acid (K2-EDTA) 
containing tubes) and biomarkers assays (tubes containing blood activators), as 
well urine samples. Subjects with previous medical histories or radiographic 
features of rheumatoid arthritis and other inflammatory arthropathies in the 
knees were excluded from the study.  
A population-based cohort was selected from three Family Doctor (FD) 
registers of the small towns of Elva and Võru, in southern Estonia. The first 
questionnaire was mailed to all 1793 individuals aged 35–57 years registered 
with these FDs. Altogether, 964 individuals responded (54%). Of these, 506 
confirmed the presence of KOA complaints (knee pain: 65%, other problems 
e.g. crepitus and stiffness: 35%), and the remaining 458 said they had no KOA 
problems. A further 475 (among them, 67% female) of the 964 responders 
agreed to in-depth clinical examinations, and, of these, 308 subjects reported 
knee problems (pain: 70%, other symptoms: 30%). Thus the study group 
included 26.5% of the subjects of the selected age group. In 33 subjects (14 
women) blood DNA samples were not available and in four subjects (three 
women) data on knee joint radiographic examinations were missing. So, the 
final population-based study group consisted of 437 subjects (302 women, 135 
men), with a mean age of 45.2 years. 
The arthroscopy group consisted of 91 subjects (including 49 women and 42 
men) aged 32−60, with a mean age of 47.4, and they had undergone knee 
arthroscopy due to chronic knee problems (several months to years prior) in 
Tartu University clinics in 2007−2010. Of those, in 44 subjects (24 women, 20 
men), aged 32−60, with a mean age of 46.7, synovial and cartilage tissue 
biopsies were available for histological examination and total RNA extraction.  
The current study was conducted as part of a large interdisciplinary project, 
having the task of a multifaceted inquiry into osteoarthritis in an Estonian 
cohort. All participants completed short-form health surveys (SF36), 
questionnaires about knee problems (Knee injury and Osteoarthritis Outcome 
Score: KOOS) and previous medical history forms. In all of the participants, 
radiographic evaluation of KOA, as well as assessment of bone and cartilage 
OA biomarkers, had previously been done (Kumm et al., 2009).  
Written informed consent for participation was obtained from each subject 
according to the Declaration of Helsinki. The study protocol was approved by 
the Ethics Committee for Human Research of the University of Tartu. 
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The allocation of study subjects and study design is presented in Table 2 
 
Table 2. Design of undertaken study and allocation of study subjects. 







Genetic association study of ADAM12 and 
CILP SNPs with rKOA (N=437) 
437 – I, II 
ADAM12-S protein assay * (N=276) 185 91 III 
Evaluation of histological synovitis in 
rKOA (N=44) 
– 44 IV 
Evaluation of synovial ADAM12 and  
CILP mRNA and protein expression in 
rKOA (N=44) 
– 44 IV, V, VI 
SNP: single nucleotide polymorphism 
rKOA: radiographic knee osteoarthritis 




6.2.1. Radiographic examination 
For radiographic assessment in the tibiofemoral joint (TFJ), standardised 
weight-bearing antero-posterior radiographs of both knees were performed. 
Axial radiographs of the patellofemoral joint (PFJ) were taken in the standing 
position, with 60°flexion of knee joints, according to the Boegård technique 
(Boegård et al., 1998a). The two main features of KOA, the presence of JSN 
and OPH development, were estimated independently in both TFJ and PFJ, 
according to the grading system (grades 0–3) of Nagaosa et al. (Nagaosa et al., 
2000). The highest grade of JSN or OPH was regarded as the stage of KOA in 
the corresponding joint (TFJ or PFJ). The highest grade of OA for each subject 
in TFJ or PFJ was regarded as the global stage of KOA. The distributions of 
rKOA, age and BMI in the genetic investigation group, the biomarkers assay 
group and the mRNA expression and immunostaining group are presented in 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3b. The distribution of radiographic knee osteoarthritis (KOA) and main 
characteristics of subjects with investigated synovial expression of ADAM12 and CILP 
mRNA. 

































Age (years, mean±SD)  46.7 ± 6.0 47.2 ± 5.4 46.3 ± 6.5 
BMI (mean±SD) 28.5 ± 5.0 29.3 ± 4.5 27.9 ± 5.2 
BMI: body mass index 
 
6.2.2. Genotyping of selected SNPs in ADAM12 and CILP genes 
Four SNPs in ADAM12–rs3740199 (c.142G>C, p.Gly48Arg), rs1871054 
(c.1154+145G>A), rs1278279 (c.1515G>A, p.Asn505Asn) and rs1044122 
(c.2475T>C, p.Ala825Ala)–and one SNP in CILP genes–rs1561888 (c.-106–
412C>T)–were genotyped in all participants. Rs3740199 in the second exon is a 
non-synonymous polymorphism, which results in substitution of amino acid 
glycine to arginine at position 48 in the ADAM12 protein. Recently, a rare new 
single nucleotide variation at the same position was revealed by sequencing 
(c.142G>T, p.Gly48Trp), with a frequency of 0.2% in the European population 
(Database of Single Nucleotide Polymorphisms). Since our study was 
performed before this rare variant was revealed, the used methodology did not 
allow us to identify this allele. The rs1278279 and rs1044122 lying in exon 14 
and exon 21, respectively, were synonymous substitutions, which did not 
change the encoded amino acid, and rs1871054 was intronic SNP in 11. intron 
of the ADAM12 gene. The SNP rs1561888 was located in the 3`-UTR of the 
CILP gene. The selection of ADAM12 and CILP genetic variants for the current 
study was performed based on previously published data of genetic association 
studies in different cohorts (Loughlin, 2005; Valdes et al., 2004; Valdes et al., 
2006). The list of laboratory techniques used is presented in Table 4. 
DNA was extracted from whole EDTA-blood by phenol-chloroform 
extraction (John et al., 1991) or by salting (Aljanabi et al., 1997) (Table 4). In 
189 subjects of the population-based cohort, rs3740199 and rs1871054 SNPs 
were amplified by polymerase chain reaction (PCR) and analysed by restriction 
fragment length polymorphism (RFLP) (Figure 5 and Table 4). The primers and 
restrictases used are shown in Table 5. In another 248 participants, rs3740199 
and rs1871054 were genotyped using TaqMan® SNP Genotyping Assays 
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(C_1419869_1 and C_12049599_10). The rs1278279 and rs1044122 in the 
ADAM12 gene and rs1561888 in CILP were detected by TaqMan® SNP 
Genotyping Assays (C_3077142_1, C_3077192_10 and C_1839361_1, Applied 
Biosystems, Foster City, CA) in all subjects (Table 4). Each sample of extracted 
DNA was normalized to a concentration of 10 ng/μl using DNAse-free water. 
The quantitative PCR assay was performed using an ABI PRISM 7000 SDS 
 
Table 4. Brief characteristics of techniques used in the current study. 
Laboratory work Used techniques 
DNA extraction Salting, phenol-cholophorm method 







RFLP: rs3740199, rs1871054 
TaqMan ®SNP genotyping assay:  
rs3740199, rs1871054, rs1044122, rs1278279 
 
RFLP; TaqMan ®SNP genotyping assay: rs1561888 
ADAM12-S protein 
measurement  
DELFIA1/AutoDELFIA® ADAM12 research kit: 
sandwich-type DELFIA assay 
RNA extraction Qiagen Rneasy® Mini kit 
Qiagen Rneasy® Fibrous Tissue kit 
mRNA synovial expression 
of ADAM12 and CILP 
TaqMan® gene expression assay: 
ADAM12: ADAM12-L, ADAM12-S, ADAM12-B 
(primers identical for both) 
CILP: CILP1 
ADAM12 protein synovial 
expression 
Immunochistochemistry: Abcam Ltd, ab56366 
CILP1 protein synovial 
expression 
Immunochistochemistry: Ab CILP1-1, Ab CILP1-2 
(courtesy of Prof. Dick Heinegård, Lund University, 
Sweden) 
Synovitis examination Formalin-fixed paraffin-embedded sections stained by 
haematoxylin-eosin and by Van Gieson method 
RFLP − restriction fragment length polymorphism 
 
analyser. Each assay well had a 5-μl reaction volume, consisting of 2.5 μl of 
20X TaqMan Universal PCR master mix (Applied Biosystems, Foster City, 
CA), 0.06 μl of 40x TaqMan primers, 1.5 μl of DNAse-free water and 1 μl of 
DNA. The amplification was performed according to the standard protocol of 
the TaqMan® Allelic Discrimination Protocol. The regenotyping of rs1561888 




6.2.3. Assay of ADAM12-S protein and  
other OA biochemical markers 
For the assays, the sera from 276 subjects (165 women, 111 men) were used: 
185 samples (116 women, 69 men) from the southern Estonian population-
based cohort and 91 samples (49 women, 42 men) from the arthroscopy group. 
Serum samples from the population-based group, based on previously known 
radiographic diagnoses of KOA for stage 0, stage 1 and stages 2−3, were 
randomly selected from available blood specimens. The extracted sera were 
stored at −20Cº until measurement. The concentrations of ADAM12-S protein 
in the serum samples were measured using the DELFIA1/AutoDELFIA® 
ADAM12 research kit (Perkin Elmer Life and Analytical Sciences, Turku, 
Finland; Table 4), according to the producer’s manual (Valinen et al., 2009). 
The sensitivity of the assay was 0.19 μg/l, defined as two standard deviations 
above the single at zero dose, measured over 10 replications. 
 
 
Figure 5. The genotyping of rs3740199, rs1871054 (ADAM12 gene) and rs1561888 






















Table 5. Primers and restrictases used for the genotyping of rs3740199 and rs1871054 
in the ADAM12 gene and rs1561888 in the CILP gene by restriction fragment length 
polymorphism technique. 
rs3740199 
(ADAM12)     
  Forward primer 5` GGA TCC CTC ATC AGC ACT GTC AC 3´ 
  Reverse primer 5`GCT CAT GAA GTT AGA GCC T 3´ 
  Restrictase PpiI 
rs1871054 
(ADAM12)   
  
  Forward primer 5`TCT GCT TTG ACA GTG TGC ATG GCT 3’ 
  Reverse primer 5` GCT CTC CAG AGT ACA GGT CAC 3` 




  Forward primer 5` TCA CAC AGG CGG GTA CAT ATT AAG GTC 3’ 
  Reverse primer 5` AGA AAT GTG TTC CAG CTG CAG CC 3´ 
  Restrictase PagI 
 
In all subjects in this group, the following markers had previously been 
measured: marker of cartilage collagen resorption−u-CTX-II and bone markers 
s-PINP and s-CTX-I (Kumm et al., 2009). U-CTX-II was assayed using the  
U-CartiLaps®ELISA kit (Immunodiagnostic Systems, Herlev, Denmark). The 
values of u-CTX-II were corrected for urinary creatinine, which was measured 
by Jaffe’s kinetic method. Bone markers were measured on the Elecsys 2010 
automated analyser (electrochemiluminescent sandwich immunoassay, Roche). 
 
Calculation of comorbidity index 
Based on the questionnaire responses, previous medical history information, 
medications used and other lifestyle factors were analysed. A comorbidity index 
(CI) was calculated based on the Functional Comorbidity Index (Groll et al., 
2005), relying on self-reported available medical histories. Finally, CIs were 
created by adding one point to the index for the presence of each of the 
following: hypertension, diabetes, history of cancer, lung disease (chronic 
obstructive pulmonary diseases and asthma), gastric or duodenal ulcers, 





6.2.4. Assays of ADAM12 and CILP mRNA expression  
in synovial and cartilage samples 
Synovial tissue samples (weight 10−50 mg) were harvested from synovial 
capsules (from macroscopic lesions) using biopsy forceps (Piranha Rongeur, 
Atlantech) for the histological evaluations and total RNA extractions. In 10 of 
the 44 patients, second samples of the tissue were obtained from a macro-
scopically unchanged synovium (suprapatellar recessus). Articular cartilage 
biopsies (weight 10−45 mg) were obtained from the medial and lateral condyle 
of the femur. 
 
RNA extraction from the biopsies of cartilage and synovial membrane 
The obtained biopsies were immediately stabilized in 300 μl of RNAlaterTM 
(Ambion, Inc., Austin, TX) solution overnight at 4 ºC and stored at −80 ºC until 
RNA extraction. All synovial tissue samples were ground after thawing using a 
T10 basic ULTRATURRAX ® dispenser (IKA® Werke GmbH & Co. KG, 
Staufen, Germany) and additionally homogenized with a syringe (needle G20). 
Total RNA was isolated from the homogenized synovial tissue samples using a 
Qiagen Rneasy® Mini kit or Qiagen Rneasy® Fibrous Tissue Mini kit 
(QIAGEN, Valencia, CA, Table 4), according to the provided manufacturer’s 
manuals. 
The yield of total RNA was detected by NanoDrop® NT-1000 spectropho-
tometer (NanoDrop Technologies, Inc., Montchanin, DE, USA), and RNA 
integrity was analysed by an Agilent RNA 6000 Nano Chip on an Agilent 2100 
Bioanalyser (Agilent Technologies, Santa Clara, CA, USA). The total RNA 
extracted from cartilage tissue showed insufficient quality (RNA integrity 
index–RIN−from undetectable to 3.1) and therefore cartilage samples were 
excluded from further study. The RIN of total RNA from synovial samples was 
in the range 6.1−10 (a mean of 8.2). All samples with RIN over 6 were included 
in the study. 
 
Synthesis of cDNA 
Reverse transcription was performed using oligo-dT(18) primers and a 
Superscript III reverse transcriptase (Invitrogen Ltd, Paisley, UK), according to 
the manufacturer’s manual. A RiboLock RNase Inhibitor (Fermentas) was used 
to inhibit the activity of RNases. cDNA was stored at −80°C until used in 
quantitative PCR. 
 
TaqMan real-time PCR 
TaqMan quantitative real time PCR (RT-PCR) was conducted to measure the 
expression of ADAM12 and CILP. Three different TaqMan® gene expression 
assays (Hs00185774_m1, Hs00222216_m1 and Hs01106104_m1; Applied Bio-
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systems, Foster City, CA) were selected for the detection of the expression of 
ADAM12−isoform I (ADAM12-Long or ADAM12-L), isoform II (ADAM-
Short or ADAM-S), and total ADAM12 (ADAM12-B, assay for identical regions 
of both isoforms), respectively. A TaqMan primer probe Hs001736147_m1 was 
used for the quantification of CILP expression (Table 4). Human β-actin 
endogenous control (Primer-Limited) (Applied Biosystems) was used as a 
housekeeping gene. 
The quantitative RT-PCR assays were performed by an ABI PRISM 
7900 HT SDS (Applied Biosystems) in 384-well plate format, according to the 
standard protocol (TaqMan® Gene Expression Assays Protocol). The PCR 
reaction was performed in three parallels. The data were analysed using the 
Sequence Detection Systems software, version 2.2.2 (Applied Biosystems). The 
RT-PCR reactions were performed as a multiplex (the housekeeper and gene of 
interest in the same well). The relative quantification levels of the gene 
expression were calculated using the 2–ΔΔCT method (CT=crossing points, cycle 
number where the fluorescence crossed the threshold 0.1): ΔCT=CT (target 
gene)-CT (reference gene); ΔΔCT=ΔCT (patients)-ΔCT (reference) (Livak et 
al., 2001). An acceptable standard deviation between the parallels was assigned 
as 0.2 and in the case of mean CT over 36 cycles as 0.4. The cDNA of a 
macroscopically non-pathological synovial specimen was used as a reference 
sample for all other synovial biopsies.  
 
6.2.5. Evaluation of histological synovitis 
Paraffin blocks for microscopical investigation were available for 42 of the 44 
patients. The biopsy samples obtained from two subjects were determined to be 
unsuitable for histological evaluation and were therefore excluded from the 
study. Histological evaluation was performed by a clinical pathologist on 
formalin-fixed paraffin-embedded sections stained by haematoxylin-eosin and 
by Van Gieson method (Table 4). The microscopic features of synovitis were 
evaluated according to the system proposed by Loeuille et al. (Loeuille et al., 
2005). Six parameters were evaluated separately: (1) number of synovial lining 
cells, (2) subsynovial infiltration by lymphocytes and plasma cells, (3) surface 
fibrin deposition, (4) congestion related to blood vessel vasodilatation and/or 
proliferation, (5) fibrosis, and (6) perivascular edema. Each parameter was 
scored on a range of 0−3. The sum of scores based on the six described 
parameters provided the final grade of histological synovitis, which was 







6.2.6. Evaluation of protein expression in the synovial membrane 
Immunohistochemistry of the ADAM12 protein 
Deparaffinised sections were treated with 3% H2O2 to inactivate endogenous 
peroxidase and then with Dako REAL Antibody Diluent (S2022; Dako Den-
mark A/S, Glostrup, Denmark) to block non-specific binding. After blocking, 
sections were incubated with mouse monoclonal antibody to ADAM12 
(ab56366; Abcam Ltd, Table 4) overnight at 4°C. The primary antibody con-
centration was 3 µg/ml. Visualization of the primary antibodies was performed 
using the commercial kit “Dako REAL™ EnVision™ Detection System, 
Peroxidase/DAB+, Rabbit/Mouse” (K5007; Dako Denmark A/S). The washing 
steps in between were done in phosphate-buffered saline (PBS), which con-
tained 0.07% of Tween 20 as a detergent. Toluidine blue (Applichem, 
Darmstadt, Germany) was used for background staining.  
Samples were evaluated in a semi-quantitative manner by two examiners as 
follows: no staining=0, mild staining=1 (a few stained cells in the field; 
magnification 40x), moderate staining=2 (more than five stained cells), and 
strong staining=3 (more than 10 stained cells). No immunohistochemical 
staining was noted in negative control samples where the primary antibody was 
omitted. 
 
Immunohistochemistry of CILP1-1 and CILP1-2 proteins 
Deparaffinised sections were treated with 3% H2O2 to inactivate endogenous 
peroxidase. The sections were then treated with hyaluronidase solution at a 
concentration of 80 IU/ml (HYA01; FertiPro N.V., Belgium) for 60 minutes at 
37°C and proteinase K solution at a concentration of 30 µg/ml (AppliChem 
GmbH, Germany) for 30 minutes at 37°C, to improve antibody penetration of 
the tissue section. Then the sections were treated with Dako REAL Antibody 
Diluent (S2022; Dako Denmark A/S, Glostrup, Denmark) to block non-specific 
binding. After blocking, sections were incubated with rabbit polyclonal 
antibody to CILP1-1 or CILP1-2 (courtesy of Prof. Dick Heinegård, Lund 
University, Sweden; Table 4) overnight at 4°C. The primary antibody 
concentration was 500 ng/ml for both antibodies. Visualization of the primary 
antibodies was performed using the commercial kit “Dako REAL™ EnVision™ 
Detection System, Peroxidase/DAB+, Rabbit/Mouse” (K5007; Dako Denmark 
A/S, Glostrup, Denmark). The washing steps in between were done with PBS 
which contained 0.07% of Tween 20 as a detergent. Toluidine blue (Applichem, 
Darmstadt, Germany) was used for background staining.  
To control immunostaining specificity with CILP antibodies, additional 
blocking with CILP1 peptides was performed. Peptides CILP1-1 and CILP1-2 
(courtesy of Prof. Dick Heinegård, Lund University, Sweden) were re-
suspended in DSMO with a final concentration of 10 mg/ml in blocking 
solution. Rabbit anti-CILP1-1 or anti-CILP1-2 polyclonal antibody was added 
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to the solution and the mixture was incubated for one hour at room temperature. 
After incubating, the immunostaining was continued according to the protocol 
described in the previous chapter. 
Samples were evaluated in a semi-quantitative manner by two examiners as 
follows: no staining=0, mild staining=1 (less than five blood vessels with 
stained cells in the field (magnification 40x)), moderate staining=2 (more than 
five blood vessels with stained cells). No immunohistochemical staining was 
noted in negative controls where the primary antibody was omitted. 
 
6.2.7. Statistical analysis 
All the analyses were carried out in an R-environment ver. 2.4.0 (The R 
Foundation for Statistical Computing, Boston, MA). 
 
SNPs associations study 
For the estimation of associations between haplotypes of selected SNPs and 
radiological traits of OA, a haplo.stats (R-project, haplo.cc) package was used. 
The Hardy-Weinberg equilibrium (HWE) was evaluated using the genetics 
package (R-project, HWE. test). A p-value of 0.05 was designated as 
statistically significant.  
The allele frequencies of genotyped SNPs were compared to those reported 
previously for the European population within the HapMap project (HapMap 
Population Diversity) and the Nottingham cohort (Valdes et al., 2006), using the 
Yates chi-square test.  
Power estimates were performed using the Quanto ver. 1.2.4 software with 
the following options: population risk of 12%, significance level 0.05, log 
additive inheritance model (Quanto software). The results of the linkage 
disequilibrium (LD) mapping were generated using Haploview software (Barret 
et al., 2005). 
The association between the SNPs and different radiographic features of 
KOA was evaluated using the logistic regression model. The ages, body mass 
indices and genders of the subjects were used as the covariates in all statistical 
calculations. To correct for the effects of multiple comparisons, we used the 
false discovery rate control of Benjamini and Yekutieli (the B-Y method), 
which provides an acceptable balance of type I and II errors. 
 
Biomarkers analysis 
Spearman’s rank correlation (SRC) analysis was applied to investigate the 
associations between the level of ADAM12-S protein and other biomarkers or 
radiographic features of KOA. Owing to the asymmetric distribution and tied 
values of ADAM12-S, a permutation test (100000 simulations) was used to 
correct Spearman’s rho test p-values. Additionally, the Bonferroni correction 
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was applied to avoid an inflated risk of type I error, and a p-value of 0.006 was 
designated as significant. The Wilcoxon rank sum exact test (WET) was used 
for comparison of the ADAM12-S values in subjects with and without 
radiographic traits of KOA. 
 
ADAM12 and CILP mRNA expression analysis 
SRC test was used to determine the association between mRNA relative 
expression level (2–ΔΔCT), the grade of histological synovitis, and protein 
expression in the synovial membrane. As the data did not fit normal distri-
bution, WET was used to compare gene expression in patients’ groups with 
different grades of rKOA. The Kruskal-Walls test or WET (if only two 
genotypes were detected in the study group) was applied for the evaluation of 
the association between mRNA expression level and genotyped polymorphisms. 
 
Immunohistochemical staining (IHC) 
SRC test was used to determine the correlation between IHC and gene 
expression level. The multiple linear regression was applied for evaluation of 
the association between IHC, histological synovitis and KOA radiographic 
features (age and BMI were used as covariates). The CILP1-1 IHC associations 
with CILP mRNA expression were additionally evaluated by a logistic linear 














 7.1. Associations of ADAM12 gene and protein with 
radiographic knee OA and OA-associated synovitis 
7.1.1. An association study for ADAM12 gene SNPs  
(Papers I and II) 
The distribution of genotypes and minor allele frequencies (MAF) of the 
investigated SNPs in the ADAM12 gene are shown in Table 6. All genotypes in 
our study groups were found to be in HWE. The MAF of all genotyped SNPs 
were similar to those reported by other studies of subjects of European descent 
(HapMap Project; Valdes et al., 2006). The degree of linkage disequilibrium 
(LD) within the ADAM12 gene was found to be predominantly weak 
(D`0.01−0.53); a strong LD (D’>0.8) was found only between rs1044122 and 
rs1278279, showing that these two polymorphisms belonged to one haploblock 
(see Paper II, Figure 1). 
 
ADAM12 and early radiographic KOA (grade 0 versus grade 1) 
The T allele of rs1044122 carried the increased risk of early rKOA in TFJ in the 
women’s group (OR 1.63, cor.p=0.038; Table 7), whereas no such association 
was observed for men or for the group as a whole. Of the KOA radiographic 
features, rs1044122 was associated only with the presence of OPH in TFJ (OR 
1.57, cor.p=0.038; Table 7). 
 
ADAM12 and advanced radiographic KOA (grade 0 versus grade ≥2) 
Differently from early rKOA, the genetic impact of the ADAM12 gene on more 
advanced (grade≥2) rKOA development was noticed only in male subjects. In 
our study group, the C allele of rs1871054 carried the highest risk for the 
appearance of advanced rKOA features (Table 8), mostly related to radiological 
changes in TFJ (OR 3.82, cor.p=0.023; Table 8). Again, of the rKOA features, 
the genetic risk was associated with osteophytosis in TFJ (OR 3.03, 
cor.p=0.038; Table 8).  
The study power for investigated SNPs varied from 88−91% at minimum 
OR 1.3. For sr3740199 and rs1278279, no statistically significant associations 
with rKOA were found.  
Taken together, in our group two ADAM12 gene SNPs demonstrates 







Association of ADAM12 gene haplotypes with radiographic KOA 
Haplotype analysis revealed that two haplotypes of ADAM12 gene were 
associated with increased risk of rKOA (see Paper II, Table 4). The most 
significant association was observed for haplotype CCAT (rs3740199, rs1871054, 
rs1278279 and rs1044122) in male subjects, which was found to be related to 
increased risk of OA in TFJ (p=0.014). Of the two main rKOA features, risk was 
predominantly associated with the occurrence of OPH (p=0.014).  
 
Table 6. The distribution of minor alleles and genotypes of investigated SNPs 
in ADAM12 and CILP genes. 
ADAM12 gene 
rs3740199  All  Men Women 
MAF C allele  35% 37% 33% 
Genotypes GG  189 56 133 
 GC  194 58 136 
 CC  54 21 33 
rs1871054      
MAF C allele  50% 47% 50% 
Genotypes CC  102 30 72 
 CT  228 68 160 
 TT  107 37 70 
rs1278279      
MAF A allele  16% 17% 15% 
Genotypes GG  310 92 218 
 AG  116 40 76 
 AA  11 3 8 
rs1044122      
MAF C allele  36% 36% 35% 
Genotypes TT  181 56 125 
 CT  200 60 140 
 CC  56 19 37 
CILP gene 
rs1561888      
MAF G allel  45% 48% 43% 
Genotypes AA  123 31 92 
 AG  238 78 160 
 GG  76 26 50 
MAF – the frequency of minor allele 
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Table 7. The associations of rs1044122 SNP in the ADAM12 gene with early radiographic knee 
osteoarthritis (OA). 
Rs1044122  Grade 0 Grade 1 OR (95%CI) p-value 
corrected  
p-value** 
  OA in TFJ 
All T allele 61% 68% 1.37 (1.01−1.87) 0.042 NS 
  TT 82 (39%) 79 (43%) 2.43 (1.17−5.05) 0.017 0.036 
  CT 93 (45%) 92 (50%) 3.26 (1.10−4.62) 0.026 NS 
  CC 34 (16%) 14 (7%) 1* 1*  
Women T allele 60% 70% 1.63 (1.12−2.37) 0.018 0.038 
  TT 53 (37%) 58 (44%) 3.78 (1.5−9.54) 0.005 0.010 
  CT 66 (46%) 65 (50%) 2.92 (1.18−7.23) 0.021 0.043 
  CC 25(17%) 8 (6%) 1* 1*  
Men T allele 65% 63% 0.90 (0.51−1.59) NS NS 
  TT 30 (45%) 21 (38%) 0.99 (0.28−3.47) NS NS 
  CT 27 (40%) 28 (51%) 1.38 (0.40−4.78) NS NS 
  CC 10 (15%) 6 (11%) 1* 1*  
  OPH in TFJ 
All T allele 62% 68% 1.33 (0.97−1.81) NS NS 
  TT 95 (40%) 67 (42%) 2.44 (1.22−4.88) 0.021 0.044 
  CT 107 (45%) 81 (51%) 2.32 (1.17−4.60) 0.021 0.044 
  CC 38 (16%) 11 (7%) 1* 1*  
Women T allele 60% 70% 1.57 (1.08−2.29) 0.018 0.038 
  TT 61 (37%) 50 (45%) 3.81 (1.42−10.23) 0.008 0.017 
  CT 76 (47%) 56 (50%) 3.09 (1.17−8.16) 0.023 0.048 
  CC 27 (16%) 6 (5%) 1* 1*  
Men T allele 65% 63% 0.90 (0.51−1.59) NS NS 
  TT 34 (45%) 17 (37%) 1.09 (0.30−3.91) NS NS 
  CT 31 (41%) 24 (52%) 1.70 (0.49−5.99) NS NS 
 CC 11 (14%) 5 (11%) 1* 1*  
OA in TFJ−radiographic osteoarthritis in tibiofemoral joint; OPH−osteophytes; *CC genotypes were analysed 
as the base; NS−non-significant.  
** For multiple comparison correction, the Benjamini & Yekutieli method was used. Statistically significant 





Table 8. The associations of rs1871054 in the ADAM12 gene with advanced (grade≥2) knee 
osteoarthritis (OA). 
Rs1871054  Grade 0 Grade 2-3 OR (95%CI) p-value 
corrected 
p-value** 
  OA in TFJ 
All C allele 50% 55% 1.37 (0.80−2.36) NS NS 
  CC 47 (22%) 14 (36%) 1.87 (0.66−5.32) NS NS 
  CT 119 (57%) 15 (38%) 0.66 (0.25−1.70)  NS NS 
  TT 45 (21%) 10 (26%) 1* 1*  
Men C allele 45% 73%  3.82 (1.36−10.73) 0.011 0.023 
  CC 12 (18%) 8 (62%) 10.11 (1.29−79.45) 0.028 NS 
  CT 35 (53%) 3 (23%) 1.26 (0.17− 9.54) NS NS 
  TT 19 (29%) 2 (15%) 1* 1*  
Women C allele 53% 46% 0.84 (0.43−1.65)  NS NS 
  CC 35 (24%) 6 (23%) 0.49 (0.15−1.56)  NS NS 
  CT 84 (58%) 12 (46%) 0.70 (0.18−2.77)  NS NS 
  TT 25 (17%) 8 (31%) 1* 1*  
  OPH in TFJ 
All C allele 51% 55% 1.30 (0.76−2.21) NS NS 
  CC 56 (23%) 14 (37%) 1.64 (0.60−4.49)  NS NS 
  CT 134 (56%) 14 (37%) 0.59 (0.23−1.51)  NS NS 
  TT 50 (21%) 10 (26%) 1 1  
Men C allele  47% 73 % 3.03 (1.11−7.53) 0.018 0.038 
  CC  16 (21%) 8 (62%) 6.63 (1.15−38.17) 0.034 NS 
  CT  39 (51%) 3(23%) 1.66 (0.30−9.40) NS NS 
  TT  21 (28%) 2 (15%) 1* 1*  
Women C allele 53% 46% 0.84 (0.43−1.64)  NS NS 
  CC 40 (24%) 6 (24%) 0.72 (0.19−2.68)  NS NS 
  CT 95 (58%) 11 (44%) 0.46 (0.15−1.43)  NS NS 
  TT 29 (18%) 8 (32%) 1* 1*  
TFJ − tibiofemoral joint; OPH−osteophytes; * TT genotypes were analysed as the base; NS − non-significant. 
** For multiple comparison correction, the Benjamini & Yekutieli method was used. Statistically significant 
p-values are indicated in bold. 
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7.1.2. The association of ADAM12-S protein with radiographic 
knee OA and OA biomarkers (Paper III) 
The ADAM12-S protein in the study group and correlation with rKOA 
The ADAM12-S protein was found in detectable values in 43 subjects (15.6% 
of the total) in the range of 0.03–14.66 μg/l, with no statistical difference 
between the genders (p=0.41, WET). In another 233 participants, the level of 
ADAM12-S was below detection limits (Table 9, Figure 6).The level of 
ADAM12-S protein did not correlate with age or BMI in the investigated 
subjects. 
 
Table 9. The characteristics of observed ADAM12-S protein values in the study group. 
  Range Median Mean 
ADAM12-S,µg/l    
All 0−14.66 0.0 0.448 
Men 0−13.70 0.0 0.297 
Women  0−14.66 0.0 0.543 
 
The level of ADAM12-S protein was significantly higher in the sera of patients 
with advanced grades (grades 2 and 3) of OPH (W=3427.5, p=0.0008, WET), as 
well as the late stage of rKOA in TFJ (W =3060.5, p=0.0015, WET) or PFJ 
(W=3476.5, p=0.0004, WET), when compared with the subjects without rKOA 
traits (grade 0). 






























The correlation between ADAM12-S protein and other OA biomarkers. 
No correlation was observed between the u-CTX-II levels and the ADAM12-S 
values in the whole group (see Paper III, Table 2). However, there was a trend 
toward a positive correlation between ADAM12-S protein and u-CTX-II in 
female subjects (ρ=0.213, p=0.019, SRC). No statistically significant corre-
lations between levels were observed for s-CTX-I or s-PINP and ADAM12-S 
protein. 
Briefly, the ADAM12-S protein in our study was found in significantly 
higher concentrations in subjects with advanced rKOA than in participants 
without rKOA features, which may suggest up-regulation of ADAM12 produc-
tion in advanced diseases. 
 
7.1.3. The expression of ADAM12 mRNA in synovial tissue and  
its association with knee OA and histological synovitis  
(Papers IV and V) 
The expression level of ADAM12 mRNA in synovial tissue  
All three isoforms of ADAM12 were expressed in synovial tissue. Of the two 
ADAM12 isoforms, synovial expression was much higher for ADAM12-L (see 
Paper IV, Figure 1). The proportion of secretable ADAM12-S represents only 
4% of the overall expression of ADAM12 in the synovium. The ADAM12 
mRNA expression was not related to the ages or BMIs of subjects and was 
similar in men and women. There was no difference in ADAM12 mRNA 
expression in samples of macroscopically pathological and non-damaged 
synovial membrane collected from the same person. 
 
Association of ADAM12 mRNA expression with histological synovitis and 
rKOA 
In our study group, the histological synovitis features was diagnosed in 85% of 
subjects. We found a weak but significant correlation between the expression of 
ADAM12-B and the grade of histological synovitis (ρ=0.28, p=0.039, SRC; see 
Paper IV, Figure 2). This association was significant only in males (ρ=0.49, 
p=0.02, SRC). From synovitis features the expression level of both splice 
variant−ADAM12-L (ρ=0.30, p=0.028, SRC) and ADAM12-S (ρ=0.33, p=0.029, 
SRC)−weakly but significantly correlated with the grade of fibrosis of the 
synovia (see Paper IV, Figure 2). 
The relative expression values of ADAM12 mRNA in subjects with and 





The influence of polymorphisms of ADAM12 on mRNA expression level 
Our data showed that the GG homozygotes (n=36) of rs1278279 in ADAM12 
had lower relative expression levels of ADAM12-B in the synovium, compared 
to subjects with AG genotype (n=8; no AA homozygotes were found in study 
group) (W=36, p=0.03, WET). This suggests that rs1278279 could have a 
regulatory impact on ADAM12 mRNA expression. 
 
7.1.4. The synovial expression of ADAM12 protein (Paper IV) 
IHC staining revealed ADAM12 protein expression predominantly in 
macrophage and fibroblast cells in 80% of the investigated synovial samples 
(Figure 7). The ADAM12 protein expression was related to the global grade of 
histological synovitis (R2=0.11, p=0.024, linear regression) and correlated with 
the ADAM12-B mRNA expression (ρ=0.30, p=0.034, SRC). Of the two splice 
variants of ADAM12, mRNA correlation with IHC staining was noticed only 
for the short isoform (ρ=0.38; p=0.014, SRC).  
Briefly, the above results demonstrate up-regulation of ADAM12 in 
histological synovitis, and particularly in synovial fibrosis on the mRNA and 
protein levels, suggesting its possible involvement in inflammation-associated 
fibrosis development. 
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Figure 7. The expression of the ADAM12 protein in investigated synovial samples. 
ADAM12 was mainly expressed in synovial macrophages (A and B-black arrow) and 






7.2. Association of CILP gene with knee OA and  
OA-associated synovial membrane inflammation  
(Paper VI) 
7.2.1. An association study for CILP gene SNP 
After genotyping by two methods (RFLP and TaqMan® allele discrimination 
assay), the rs1561888 of the CILP gene in our study group was not in HWE 
(p=0.036), owing to the too large proportion of heterozygotes (Table 6). The 
regenotyping results of RFLP were similar, with overall discordance from the 
TaqMan® technique of 0.9 %. 
In our material, the G allele of rs1561888 carried the risk of early (grade 1) 
rKOA in PFJ (OR 1.45, 95%CI 1.08−1.94, p=0.014, cor. p=0.031). Of the two 
genders, this association was important only in female subjects (OR1.52, 
95%CI 1.07−2.17, p=0.020, cor. p=0.045). Of the two main radiographic KOA 
features, the rs1561888 was associated only with the occurrence of OPH in PFJ 
(1.41, 95%CI 1.05−1.90, p=0.022, cor. p=0.05). Again, the risk was found in 
females (1.51, 95%1.06−2.15, p=0.022, cor. p=0.052) and not in males. 
 
7.2.2. The expression of CILP mRNA in synovial tissue and  
its association with knee OA and histological synovitis 
CILP mRNA expression in synovial tissue 
In 42 of the 44 samples, the CILP mRNA calculated relative expression was in 
the range 0.01−13.99 (median=0.33) and in two samples it was calculated as 
zero. CILP expression was not related to the ages, BMIs, genders or reported 
physical activities of the investigated subjects. No difference in CILP mRNA 
expression was noticed in inflamed and macroscopically intact synovial 
membrane from the same subject. 
 
CILP mRNA expression in rKOA 
The expression of CILP mRNA in the synovial tissue was significantly lower in 
patients with advanced stages (grade≥2) of JSN in TFJ, compared to subjects 
without changes in the joints (W=104, p=0.0006, WET). This difference was 
significant only in male patients (W=33, p=0.004, WET; Figure 8). 
 
CILP mRNA expression in synovitis 
No associations were found between CILP mRNA expression and the final 
grade of histological synovitis. But there was significant correlation between 
CILP mRNA and severity of fibrosis of the synovium (ρ=0.31, p=0.026, SRC).  
These data suggest that synovial membrane can be an additional source of 
CILP production in the synovial joint and CILP synovial expression seems to be 
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down-regulated in subjects with advanced cartilage degradation (narrowing of 
joint space). 
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Figure 8. The association of CILP mRNA expression in synovia with joint space 
narrowing (JSN) in the study group. The expression level of CILP mRNA was 
significantly lower in male patients with late stages of radiographic diseases (A). No 
such differences were observed in females (B). 
 
7.2.3. The synovial expression of CILP1 protein 
Immunostaining with CILP1-1 antibody detected protein in 22 of the 42 
subjects (52%). The CILP1-1 protein in synovial membrane localized mainly in 
the media and adventitia layers of blood vessels, but also extracellularly in 
connective tissue, mainly in macrophage-like and fibroblast-like synoviocytes 
(Figure 9). 
Surprisingly, the CILP mRNA expression correlated negatively with  
CILP1-1 IHC (ρ= –0.33, p=0.018, SRC; Figure 10). Additionally, CILP1-1 
protein expression in synovial tissue was in negative correlation with the ages 
of the investigated subjects (ρ= –0.38, p=0.013). No specific IHC staining was 
observed for CILP1-2 in synovial tissue (Figure 9).  
Taken together, these results support the suggestion that synovia seem to be 
an additional source of CILP1 production. 
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Figure 9. The immunohistochemical (IHC) staining of synovial membrane with  
CILP1-1/2 antibody. The CILP1-1 protein in synovial membrane localized mainly in 
adventitia and the media of blood vessels (A, arrows, magnification 40x), and in the 
extracellular matrix of connective tissue (B, asterisks, magnification 20x). No IHC 
staining was observed after blocking with CILP1-1 peptide (C, magnification 40x). No 
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Figure 10. Results of CILP1-1 immunostaining and its correlation with CILP mRNA. 
CILP mRNA expression in synovial tissue correlated negatively with CILP1-1 protein 
synovial expression (Spearman rank correlation). CILP1-1 immunohistochemical 
staining was measured as follows: no staining (0), mild (1) and moderate staining (2); 






The current research focused on the implication of ADAM12 and CILP genes on 
KOA development, based on an association study of the SNPs of both genes, an 
evaluation of the protein product of the ADAM12 gene, and ADAM12 and CILP 
mRNA expression assays in synovial tissue of subjects with knee OA. In the 
current study, we demonstrated that ADAM12 is associated with rKOA 
processes at different levels (gene, protein and mRNA). We first reported 
synovial expression of CILP mRNA and protein, and revealed the similar 
behaviour of both investigated genes in synovia, which were involved in 
inflammation-induced fibrogenesis and had a greater impact on male subjects. 
 
 
8.1. ADAM12 contribution to OA processes on the gene, 
protein and mRNA levels 
8.1.1. The association of ADAM12 gene SNPs  
with radiographic knee OA 
Genetic background is an important determinant of OA. In particular, the 
identification of OA-susceptibility genes makes it possible to predict disease 
phenotypes, construct OA-prediction models and implement novel treatment 
strategies in the future. 
Our study was designed to investigate the possible contribution of selected 
genetic variants of the ADAM12 gene to rKOA in a middle-aged population 
cohort, where early rKOA was expected to be predominant. Moreover, the 
evaluation of the ADAM12 genetic contribution to different pathophysiological 
processes of OA (OPH formation and JSN) was one of the main tasks of our 
study. 
The ADAM12 gene has been only sparsely investigated in associations with 
knee and hip OA. ADAM12 was reported to be associated with an increased risk 
of the development and progression of KOA in females by the Chingford study 
(UK), whereas genetic risk has mostly been associated with the appearance of 
osteophytes (Valdes et al., 2004). Later, an extensive GOAL study (UK) was 
unable to replicate this association (Limer et al., 2009). However, a study by 
Limer et al. used conflated rKOA scores without separation of different rKOA 
features. 
The results of our study demonstrated that two ADAM12 SNPs were related 
to increased risk of rKOA in the Estonian cohort. Notably, a higher risk was 
observed for early (grade 1) as well for more advanced (grades 2−3) 
radiographic changes, suggesting continuous involvement of ADAM12 in OA 
processes from the early radiographic phase. Furthermore, it is notable that of 
the two main rKOA features SNPs in ADAM12 genes carried the highest risk 
only for the appearance of OPH in both early and late rKOA. Moreover, the 
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haplotype containing risk alleles of both SNPs also carried the risk for 
osteophytosis. This indicates the impact of ADAM12 on OPH formation and 
supports the finding that in radiographic KOA studies the two main 
radiographic features (JSN and OPH) should be evaluated separately, and the 
conflating of those into global OA can cloud the analysed information. 
Interestingly, from genotyped ADAM12 polymorphisms the statistically 
significant associations with KOA were found for synonymous SNP (sSNP) 
rs1044122 (c.2475T>C, p.Ala825Ala) and intronic variant rs1871054 
(c.1154+145G>A), suggesting the functionality of those variants in the KOA. 
Moreover, the other sSNP of ADAM12, rs1278279 (c.1515G>A, p.Asn505Asn), 
in our material influences the level of gene expression in synovial tissue, 
possibly due to changes in secondary structures of mRNA. The sSNP is 
characterized by substitution of the nucleotide in triplet without amino acid 
change in protein content. In the past decade many studies reported associations 
between synonymous SNPs and the risk of common diseases (Wellcome Trust 
Case Control Consortium, 2007). Indeed, according to recent broad survey, 
sSNPs are likely to be associated with disease as non-synonymous SNPs and 
also shared very similar effect size of disease association (Chen et al., 2010). 
The mechanisms through which sSNPs might be causal include influencing 
promoter activity and the conformation and stability of pre-mRNAs (Capon et 
al., 2004), or changing the rate of protein folding (Kimchi-Sarfaty et al., 2007). 
In the case of intronic SNP, the common molecular mechanisms for alteration 
of mRNA levels affect transcription, RNA elongation, splicing or maturation 
(Wang et al., 2011). 
Therefore, our data support the opinion that in common diseases like OA, in 
addition to amino-acid causing variants, other polymorphism like intronic and 
sSNPs are likely to be involved in the disease mechanisms. These variants 
should be included in the functional studies and under-investigation of such 
variants could lead to missing a significant number of disease-associated gene 
changes. 
Previous genetic OA studies suggest that innate sex-specific differences may 
exist at the molecular level, which may contribute to disease appearance and 
severity (Loughlin et al., 2004; Rodriguez-Fontenla et al., 2012). In addition, 
the results of our study demonstrated different contributions of ADAM12 to 
rKOA in both genders (with a higher risk of rs1044122 only in women and of 
rs1871054 only in men). This supports the putative gender-specific impact of 
the ADAM12 gene on incident OA, whose molecular basis is currently unclear. 
Since our study was not designed to determine the probable reason for this 
phenomenon, we can’t explain the observed sex-specific differences. However, 
our data, along with the results of other similar surveys, indicate that in genetic 
studies associations for both genders should be evaluated separately. 
It is well known that sample size may have an impact on results. The final 
analysis of genetic associations (Paper II) did not reveal associations for 
rs3740199 in ADAM12, with rKOA being observed in the significantly smaller 
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group (Paper I). This missense SNP results in substitution of amino acid glycine 
to arginine at position 48 in ADAM12 protein, which is expected to be 
relatively neutral for extracellular proteins (Betts et al., 2003). The reason for 
this discrepancy is probably related to the putative controversial contribution of 
this variant to KOA in men and women. For example, in our study, we found 
that a haplotype containing the C allele of rs3740199 carried the risk of OA in 
men, and a haplotype containing the G allele increased the risk in women. Also, 
it has been hypothesized that this SNP can act as a modulator of genetic 
susceptibility only in the presence of other alleles (Valdes et al., 2006).  
Moreover, in 2012 an additional variant of this SNP–the non-synonymous 
change of glycine to tryptophan (g.128019025C>A, p.Gly48Trp)–was described 
by sequencing and published in the ClinSeq project (Database of Single 
Nucleotide Polymorphisms). This variant of rs3740199 is not widely studied at 
present and seems to be very rare in the European population (0.2%). The 
genotyping of selected SNPs in our study was performed before this rare variant 
was revealed and the methodology used did not allow us to identify subjects 
with the A allele. It seems possible that if subjects with this genotype were 
present in our group they could be misdiagnosed as CC genotype. However, in 
view of the low frequency of the A allele, it is improbable that the presence of 
this variant in our study group influenced the results obtained. 
In conclusion, our data support the consideration of the ADAM12 gene as 
potentially associated with increased risk of KOA during early and late stages 
of the disease, and it seems to be predominantly related to osteophytosis (bone 
remodelling and neochondrogenesis). 
 
8.1.2. The role of ADAM12 protein in the development  
of radiographic knee OA features 
In the current study, we evaluated the relation of ADAM12-S, a protein product 
of an OA candidate gene, to rKOA and several bone and cartilage biomarkers. 
According to our results, the level of ADAM12-S increased in advanced stages 
of KOA and this elevation correlated with the severity of the disease. As with 
genetic associations for ADAM12 gene SNPs, the elevation of ADAM12-S was 
related only to one of the two main radiographic features of rKOA: 
osteophytosis in both tibio- and patellofemoral joints. This finding, along with 
previous data from genetic studies, suggests the involvement of ADAM12 in 
pathophysiologic pathways associated with OPH formation.  
Basically, osteophyte formation indicates repair attempts and seems to be 
primarily a process of neochondrogenesis of mesenchymal stem cells present in 
the periosteum. The main physiological functions of ADAM12 include three 
categories: catalytic function (mainly the processing of growth factors), 
cytoskeletal reorganization and cellular signaling; both splice variants of 
ADAM12−ADAM12-L and ADAM12-S−are active shedases (Jacobsen et al., 
2009). Experimental data demonstrate that the expression of the membrane-
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anchored form of ADAM12 (ADAM12-L) is up-regulated in chondrocytes and 
correlated with chondrocyte proliferation (Okada et al., 2008). Moreover, the 
expression of ADAM12 mRNA and protein was selectively enhanced by TGF-β, 
which in turn is a potent inducer of chondrocyte growth (Okada et al., 2008). 
The notable contribution of ADAM12 to chondrocyte proliferation seems to be 
linked to its proteolytic activity in relation to IGFBP-5, whereas the latter is a 
substrate for both ADAM12 isoforms (Loechel et al., 2000). ADAM12-
mediated cleavage of IGFBP-5 leads to the enhanced bioavailability of IGF-1 
from the IGF-1-IGFBP-5 complex, resulting in chondrocyte proliferation. The 
results of our study, demonstrating the relation of ADAM12 to osteophytosis on 
the gene and protein levels, support the importance of ADAM12 in the process 
of neochondrogenesis and bone remodelling during OA. 
Often in OA joints the development of OPH is accompanied by notable 
degradation of cartilage and can even pre-date this process. Boegård and his co-
workers reported that the appearance of OPH at both TFJ and PFJ is associated 
with MRI-detected cartilage defects, whether joint space narrowing is present or 
not (Boegård et al., 1998b; Boegård et al., 1998c). Hypothetically, owing to its 
multifunctional domain structure, ADAM12 could contribute to both main OA 
processes: the development of osteophytes and cartilage degradation. Both 
ADAM12 isoforms share pro- and catalytic domains linked to proteolytic 
activity, as well as desintegrin-like, cysteine-rich and EGF-like domains in the 
body of the protein involved in cell-binding events (Jacobsen et al., 2009). 
Indeed, several studies have found that ADAM12 may cleave ECM compo-
nents, including collagen IV, fibronectin and gelatin (Roy et al., 2004). A 
relevant study did not confirm this catalytic activity of recombinant ADAM12 
on ECM substrates (Jacobsen et al., 2009), so the role of ADAM12 as an ECM 
protease remains unresolved. The trend observed in our study of a correlation 
between ADAM12-S and the marker of cartilage degradation u-CTX-II seems 
to support the possible catalytic activity of ADAM12 related to cartilage ECM 
components and may suggest the putative relation of ADAM12 to cartilage 
matrix deterioration. 
Taking into account the putative relation of ADAM12-S to osteophytosis, 
our failure to detect a correlation between ADAM12-S and bone biomarkers  
(s-CTX-I for resorption and s-PINP for formation) may be explained by the 
biological nature of the selected biomarkers. Both s-PINP and s-CTX-I are 
markers of the turnover of type I collagen, whose strongest expression was 
experimentally detected in bone tissue. Although the expression of type I 
collagen can be found in superficial fibrous layer of osteophytes, the strong 
expression of type II collagen was demonstrated in all of the cartilaginous and 
fibrocartilaginous areas, being a hallmark of chondrogenic differentiation in the 
cartilaginous zone of osteophytes (Aligner et al., 1995). Moreover possible, that 
in process of osteophyte formation the blood level of both biomarkers will be 
changed in very small ranges, which is not sufficient for reaching statistical 
significance. 
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Taken together, our data suggest that ADAM12 may contribute to both KOA 
pathogenetic processes: the development of osteophytes (neochondrogenesis 
and bone remodelling) and cartilage degradation. Of those processes, ADAM12 
seems to have a stronger impact on OPH formation, which was observed in the 
genetic association study and on the protein level. 
 
8.1.3. The role of ADAM12 gene and  
protein in synovial inflammation 
Our results demonstrate clearly that ADAM12 is expressed in the synovial 
membrane and that the expression of this gene is up-regulated during synovial 
inflammation. Notably, this association was found not only at the gene level (as 
mRNA expression) but also in the presence of a large amount of ADAM12 
protein in inflamed synovia. In addition, our results underline the importance of 
synovial inflammation in the course of OA, which is consistent with the 
increasing body of knowledge showing that inflammatory synovitis can be an 
early feature of OA and is not restricted to patients with end-stage disease 
(Sellam et al., 2010; Attur et al., 2010). 
The involvement of ADAM12 in synovial membrane inflammation has not 
yet been investigated and only one study has reported the relatively low 
expression of ADAM12 (13% of synovial tissue biopsies) in OA samples 
(Komiya et al., 2005). In contrast, we found a much higher expression of both 
ADAM12 mRNA (100%) and protein (80%) in the investigated synovial 
membrane biopsies. This discrepancy may be related to differences in the 
primers used for the detection of expression rate: only the ADAM12-L isoform 
was measured in Komiya`s study, while both splice variants were measured in 
our research.  
The contribution of ADAM12 to inflammatory responses and tissue 
remodelling is largely unknown. Animal studies have shown that the long-term 
over-expression of ADAM12 is associated with inflammation, but also with 
accelerated fibrosis and adipogenesis in the skeletal muscle of mdx-mice 
(Jørgensen et al., 2007). Additionally, the TGF-β induced expression of 
ADAM12 has been reported to be associated with liver fibrogenesis in cultured 
human hepatic stellate cells (Le Pabic et al., 2003). The up-regulation of 
ADAM12 mRNA on fibrotic samples of the synovium observed in our study 
also suggests the possible involvement of ADAM12 in fibrosis-associated 
remodelling of the synovial membrane. Moreover, our findings are in 
agreement with a recent patent description suggesting the use of ADAM12 as a 
new regulator for inflammation-induced fibrosis for the prevention or even 
treatment of fibrosis-related complications (Peduto et al., patent 
WO/2011/024146). In the light of our study and other results, it seems 
reasonable to propose the hypothesis that inhibitors of ADAM12 could serve as 
drug candidates for modulating the course of OA.  
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TGF-β is a very potent profibrotic cytokine (Gruel et al., 2009) and strongly 
regulates the synthesis of extracellular matrix components and many proteins 
involved in their turnover, including MMPs and their inhibitors (Le Pabic et al., 
2005). Some studies have indicated that ADAM12 transcription is regulated by 
endocrine factors, including TGF-β, which has been shown to induce ADAM12 
expression via two different pathways (Le Pabic et al., 2003; Le Pabic et al., 
2005). In turn, ADAM12 is found to facilitate TGF-β signaling at the membrane 
via interaction with a type II receptor, modulating TGF-β receptor trafficking 
and controlling the localization of TGF-β receptors to early endosomes (Atfi et 
al., 2007). This suggests that ADAM12 may have a function as an important 
component in TGF-β signaling, and that ADAM12 and TGF-β may form a 
functional feedback loop in the processes of fibrogenesis. 
In our study, an association with synovial fibrosis was observed for both 
splice variants of ADAM12 (long and short). Therefore, we suggest that both 
proteins share domains functionally associated with the development of fibrosis. 
According to published data, it is probable that, in fibrogenesis, the desintegrin 
domain of ADAM12 is involved. This domain binds integrin, which is an 
important signal transducer between intra- and extracellular space (Eto et al., 
2000; Zhao et al., 2004; Thodetti et al., 2005). Furthermore, the experimental 
data suggest that surface over-expression of ADAM12 alters the activity of cell 
surface integrins, leading to cytoskeletal reorganization (Kawaguchi et al., 
2003).  
In summary, the results of our study enhance the understanding that syno-
vitis is an integral component of knee OA and that the expression of ADAM12 
is associated with synovitis even in the early phases of the disease. Moreover, 
we propose that ADAM12 may be associated with the development of synovial 
fibrosis and thereby may impair the normal function of the synovial lining. A 
better understanding of the biological and molecular mechanisms of synovial 
inflammation and of the role of ADAM12 in it could potentially lead to the 
development of new therapeutic approaches, thereby potentially slowing 
cartilage degradation. 
Considering the results of our ADAM12 study, we can state that in an 
Estonian population ADAM12 was related to incident rKOA, leading to a 
higher genetic risk, showing an increase in the patient’s serum on the protein 










8.2. The implication of CILP in synovial inflammation and 
its relation to radiographic knee OA 
8.2.1. The association of CILP gene polymorphism  
with radiographic knee OA 
The rs1561888, located in the 3-`UTR region of the CILP gene, deviated from 
HWE in our material. Generally, a departure from HWE can be explained by 
natural selection, population admixture, inbreeding, experimental errors or 
duplication (Lee et al., 2008). Clearly, genotyping errors are considered the 
most common reason for HWE imbalance. However, since our results are 
confirmed by two techniques, with a minimal difference of less than 1%, we 
believe that the genotyping of rs1561888 is correct and that the deviation from 
HWE in the investigated cohort is true. Inbreeding and population admixture 
seem not to be very reliable reasons to explain the HWE imbalance, as the 
population investigated from south-east Estonian towns is considered an open 
population that has remained relatively stable for several centuries. The 
distribution of rs1561888 genotypes in our study group revealed an excessively 
large proportion of heterozygotes. As is known, in several disorders (e.g. sickle-
cell anaemia allele carriers in malaria outbreaks, and cystic fibrosis mutation 
carriers in cholera) the heterozygotes have a higher relative fitness than either 
the dominant or recessive homozygote genotype (Gabriel et al., 1994; Bridges, 
2002). It is not excluded that this SNP may have importance in several disorders 
associated with over-dominance. 
In the case of KOA, for rs1561888 we observed associations with early 
disease. Similarly to the risk associated with rs1044122 of ADAM12 variants, 
the CILP polymorphism carried the higher risk only for OPH formation in 
women. Previously, the sex-specific effect of CILP variants in musculoskeletal 
disorders (OA and lumbar disc degeneration) has been reported in different 
ethnic cohorts (Valdes et al., 2006; Min et al., 2010). Our results support the 
gender-dependent impact of rs1561888 in KOA, whereas its functionality is 
currently unclear. Regulatory elements within the 3'-UTR region can influence 
post-transcriptional gene expression, localisation and stability of the mRNA, 
translation control as well as polyadenylation (Barret et al., 2012; Pichon et al., 
2012). A growing number of diseases stand to become linked with such 
elements and correlation between different disorders (including OA) with 
polymorphisms within the 3`-UTR has been reported (Egli et al., 2009; Pichon 
et al., 2012; Friese et al., 2013). Hypothetically, rs1561888 could be this kind of 
variant and further investigation could help to evaluate the functional impor-




8.2.2. The synovial membrane as an additional source  
of CILP production 
The current study revealed detectable CILP mRNA expression in synovial 
tissue, supporting the possibility of non-cartilaginous CILP1 production. 
Notably, this data was supported by immunochistochemical staining, which 
detected immunoreactivity with the CILP1-1 antibody in more than half of the 
investigated synovial samples. CILP1 has been detected in the intermediate 
zone of articular cartilage (Lorenzo et al., 1998a) and is thought to be highly 
specific only to this tissue. The amount of CILP1 was shown to increase in aged 
and osteoarthritic cartilage, giving rise to the suggestion of CILP1 as a 
promising OA biomarker. Recent studies have also discovered its expression in 
other tissues of synovial joints, including the meniscus (Johnson et al., 2003) 
and intervertebral disc (Seki et al., 2005). A recent study also localized CILP in 
non-cartilaginous tissue, particularly in the heart and skeletal muscle (Bernardo 
et al., 2011). Furthermore, the porcine homologue of human CILP1 was 
detected in synovial fluid (Masuda et al., 1997b), indicating the possibility that 
CILP1 could be also produced in synovia. Thus, our results support the 
suggestion that CILP1 can be considered to be not only a marker of cartilage 
homeostasis, but also a possible indicator of whole joint metabolism.  
In cartilage, CILP1 is produced by chondrocytes (Lorenzo et al., 1998a). 
Synovial tissue contains various cells, such as the pseudoepitelial lining, and 
type A macrophage-like and secretory fibroblast-like type B synoviocytes 
(Revell et al., 1998). In our study, the immunoreactivity with the CILP1-1 anti-
body in synovia was predominantly observed in the media and adventitia of 
synovial blood vessels and, in smaller proportions, diffused extracellularly in 
connective tissue (macrophage-like and fibroblast-like cells). Based on this 
observation, we suggest that the main candidates responsible for CILP1 produc-
tion in synovia could be smooth muscle cells, macrophage-like and fibroblast-
like synoviocytes. Although it has not been confirmed experimentally, our data 
suggest that CILP1 in synovial membrane, similarly to cartilage tissue, could be 
secreted and deposited in the synovial extracellular matrix by synoviocytes. 
The observed immunoreactivity with the CILP1-1 protein confirms the 
deposition of CILP1 in synovial membrane. However, the observed negative 
correlation of CILP mRNA and CILP1-1 protein is a bit confusing. Similarly, 
the discrepancies in CILP mRNA and protein expression in cartilage and in the 
intervertebral disc have also been reported by other researchers, which has been 
explained by possible alternative splicing, rapid turnover of protein or repressed 
translation (Masuda et al., 2001). Moreover, there is a suggestion that the 
expression of mRNA can capture at most 40% of the variation of protein 
expression in cultured mammalian cells, emphasizing the importance of post-
transcriptional regulatory mechanisms in cellular development (Tian et al., 
2004). The negative correlation between CILP mRNA and protein observed in 
our study may have been caused by a regulatory mechanism acting at the post-
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transcriptional level (translational repression, alternative splicing, decreased 
protein stability or reduced translation efficiency, for example through a 
blocking of the protein translation machinery).  
In conclusion, our data suggest that synovial membrane could be an 
additional source of CILP1 production in synovial joints, although the pro-
portion of CILP1 synovial production is presently unclear.  
 
8.2.3. The relation of synovial expression of CILP gene and  
protein to synovial fibrosis and radiographic knee OA 
CILP in synovial fibrosis 
Similarly to ADAM12, CILP in our study was associated with the severity of 
synovial fibrosis. The function of CILP in synovial tissue is currently unknown. 
In cartilage, CILP is thought to modulate the architecture of the cartilage matrix 
(Tsuruha et al., 2001) and may act as a TGF-β antagonist. In vitro studies have 
demonstrated that in bovine cartilage CILP expression is enhanced by TGF-β 
and inhibited by IGF-1 (Johnson et al., 2003). The TGF-β-dependent induction 
of CILP mRNA has been reported in rabbit nucleus pulposus cells (Seki et al., 
2005) and human cell lines (HeLa and HuH-7) (Mori et al., 2006), which seems 
to be basically mediated by SMAD3, acting directly through cis-elements in the 
CILP promoter region (Mori et al., 2006). Conversely, CILP1 acts as a negative 
regulator of TGF-β1, and CILP1 protein binds TGF-β1 directly in vitro (Seki et 
al., 2005). This suggests that CILP1 and TGF-β1 may form a functional nega-
tive feedback loop (Mori et al., 2006) that could control chondrocyte meta-
bolism and the production of ECM proteins. There are no experimental data 
regarding the regulation of CILP in fibrogenesis. TGF-β1 plays a central role in 
tissue repair, and excessive TGF-β1 contributes to the development of tissue 
fibrosis (Branton et al., 1999). Hypothetically, in synovial fibrosis TGF-β1-
CILP feedback might act as follows: over-expression of TGF-β1 induce the 
production of CILP mRNA, which in turn acts as a TGF-β1 antagonist, partially 
modulating TGF-β1 activity and playing a role in tissue remodelling. 
The observed CILP mRNA over-expression in our study suggests its 
involvement in the fibrogenesis of the synovial membrane, theoretically anta-
gonizing TGF-β1 activity. Since recent research has also detected an enhanced 
level of CILP mRNA in cardiac post-ischemic fibrosis (Barallobre-Barreiro et 
al., 2012), the impact of CILP in the development of fibrosis does not seem to 
be exclusively associated with OA changes. 
 
Synovial CILP expression in rKOA 
However, an OA process still seems to influence the synovial expression of 
CILP. Our results showing significant down-regulation of CILP mRNA in 
severe cartilage destruction (JSN grade≥2) suggests a possible reduction of 
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CILP synovial production in advanced disease. In contrast, in cartilage CILP 
expression was significantly up-regulated during ageing and the development of 
OA, as has been reported by previous studies (Lorenzo et al., 1998a). We are 
not yet able to explain the different expression pattern of CILP in different 
tissues of the same joint during OA. The regulation of CILP has not been 
widely studied. In addition to TGF-β1, another member of the TGF super-
family–bone morphogenetic protein 2–has been shown to induce CILP 
expression (Wang et al., 2012). Our study was not focused on the detection of 
CILP regulatory mechanisms in different tissue, so we can’t be sure which 
mechanisms are involved in the various expressions of CILP mRNA in joint 
tissues. The possible reasons could include a decrease in synovial CILP1 pro-
duction via a negative feedback mechanism (due to high simultaneous up-
regulation in cartilage), changes in the cellular composition of the synovial 
membrane or different activations of CILP regulatory pathways in synovium 
and cartilage. 
Similarly to ADAM12, CILP demonstrates a notable gender-dependent 
contribution in rKOA. In our study group, the down-regulation of CILP mRNA 
expression in subjects with joint space narrowing was observed only in male 
subjects. Notably, sport and physical activity do not influence CILP expression, 
which could explain the existing difference between genders a priori. 
Moreover, the gender specific impact of CILP in cartilage disease, including 
KOA, which seems to be more prominent in males, has been reported in genetic 
studies with different ethnic cohorts (Valdes et al., 2006; Min et al., 2009). Our 
results also suggest that the most drastic changes in CILP mRNA expression 
during KOA occur in males, although this result needs to be replicated with 
larger cohorts. 
In conclusion, our data from the CILP study demonstrate that, in addition to 
chondrocytes, CILP might be produced in synovial joints, probably by smooth 
cells of blood vessels and synoviocytes, and it plays a role in the fibrogenesis of 
the synovial membrane. The behaviour of CILP in the synovia of OA joints 
seems to be distinct from that reported in cartilage, and the molecular basis of 
this variation is currently unclear.  
 
 
8.3. Limitations of the study 
Our study has several limitations. First of all, part of the CILP study failed, as 
happens quite often in scientific work. Despite the fact that the planned genetic 
association study of rs1561888 CILP SNP generally failed in terms of Hardy-
Weinberg disequilibrium, our data may have importance in exploring other 
disorders (e.g over-domination) potentially associated with this SNP. Our 
failure in RNA extraction from cartilage biopsy samples is probably related to 
the small sample size and the extraction techniques used (manual grinding and 
extraction kits). Indeed, in most similar studies, sample tissue was obtained 
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during large surgical intervention, such as joint replacement. Joint replacement 
surgery definitely provides more material with better quality, but for an 
investigation of the early phase of the disease arthroscopic biopsy was the only 
available approach. However, our failed attempt could provide additional data 
for other researchers working in this field, suggesting the preference of 
automatic sample processing over manual for very small cartilage samples, and 
the benefit of certain RNA extraction kits.  
Secondly, for a genetic study 437 subjects is a relatively small number for 
detecting weak genetic associations. Indeed, single population-based studies 
often provide an insufficient number of participants of required ages. However, 
we had an adequate power for both ADAM12 SNPs demonstrated associations 
with rKOA. Moreover, the population-based design was the main advantage in 
this case. In large genome-wide linkage studies, as well as in smaller case-
control studies, it is quite difficult to ensure homogeneity in radiographic/ 
clinical diagnosis (e.g. heterogeneity in imaging techniques, insufficient 
radiographic evaluation of controls, and a tendency to selection and recall bias). 
In general, the Estonian population can be considered to be an open population. 
It should be noted that selecting a southern Estonia cohort was the strength of 
the current study, as the population of this region has been stable in terms of 
residence for two centuries. Thus, we investigated a small but homogeneous 
cohort and our study provides data for precise evaluation and identical clinical/ 
diagnostic testing of all recruited participants. Additionally, the recruitment of 
middle-aged subjects and focus on early rKOA could potentially reduce the 
effect of confounding co-morbidites observed in older cohorts.  
Finally, the main limitation of the ADAM12-S assay study was the small 
number of subjects with detectable protein values in their sera. In fact, the 
ADAM12 protein is expressed mainly during the development and differen-
tiation stages in fast-growing tissues, such as the placenta and malignant 
tumours (Wewer et al., 2005). Furthermore, the research kit used for the 
detection of the ADAM12-S protein in this study was mainly developed to 
measure the ADAM12 protein in the sera of pregnant women, in whom the 
median concentration is higher than 100 µg/l even in the first trimester of 
pregnancy (Laigaard et al., 2003). However, despite the essential difference in 
the prospective by the manufacturer and our real study group, we were able to 
detect ADAM12-S concentrations in more than 15% of the subjects. Obviously, 
a more sensitive ADAM12 measuring kit with lower detection limits would 










1) The present study is the first to demonstrate the association of ADAM12 
with the pathophysiological processes of knee KOA at the gene, protein and 
mRNA levels. 
2) The ADAM12 gene carried the genetic risk of KOA in an Estonian popu-
lation-based cohort. Two SNPs, belonging to different haploblocks, were 
associated with the features of radiographic KOA: the T allele of rs1044122 
in early osteophytosis (grade 1) in women, and the C allele of rs1871054 in 
more advanced (grade≥2) osteophytosis in men. This suggests the potential 
gender-specific impact of ADAM12 on the onset of the development of 
osteophytes, determining the early or more advanced disease phenotype. 
3) More advanced rKOA was characterized by the increased production of 
serum ADAM12-S protein, which was found at higher concentrations in the 
late stages of the disease. 
 This indicates the possibility that the proteolytic activity of ADAM12-S 
could be involved in the regulation of the growth and proliferation of 
chondrocytes, and contribute to osteophyte development. 
 The observed correlation between ADAM12-S and the marker of 
cartilage degradation u-CTX-II may suggest the putative relationship of 
ADAM12 with cartilage deterioration. 
4) The expression of ADAM12 mRNA and protein in synovia was up-regulated 
during synovial inflammation, especially in fibrosis, suggesting the impli-
cation of ADAM12 in fibrogenesis, most likely facilitating TGF-β signaling 
by TGF-β receptor. 
5) Cartilage intermediate layer protein (CILP1), a marker of cartilage 
metabolism and a new OA biomarker, was found in synovial tissue at the 
mRNA and protein levels. Hence, our results demonstrate that synovial 
membrane may be an additional source of CILP1 production in joints. 
 According to immunohistochemical investigation, the main sources of 
CILP1 in synovial tissue seem to be smooth muscle cells in the adventitia 
and media of synovial blood vessels, as well as macrophage-like and 
fibroblast-like cells. 
6) Similarly to ADAM12, the synovial expression of CILP mRNA was found to 
be up-regulated in fibrotic synovial samples, suggesting its involvement in 
the development of post-inflammatory fibrosis.  
7) Unlike ADAM12, the synovial expression of CILP mRNA was down-
regulated in the advanced stages of cartilage degradation (JSN), suggesting a 
decrease in CILP1 production during the advanced stages of knee OA, at 





10. SUMMARY IN ESTONIAN 
ADAM12 ja CILP geenide roll põlve osteoartiidi arengus 
Taust 
Osteoartriit ehk osteoartroos (OA) on kõige levinum multifaktoriaalne ja polü-
geenne liigeshaigus, mis võib haarata kõiki liigeseid. Kõige sagedamini esineb 
põlve-, puusa- ja käeliigeste OA. Kliiniliselt kõige olulisemaks avaldumise-
kohaks on põlveliigesed (Peat et al., 2001). Viimasel dekaadil on OA käsitlus ja 
definitsioon muutunud. Kui varem on käsitletud OA üksnes kõhre degenera-
tiivse haigusena, siis nüüdseks on selgunud, et OA haarab kõiki liigeskudesid, 
kaasa arvatud kõhr, subkondraalne luu, sünoviaalmembraan, sidemed ja lihased 
(Flores et al., 2003). Üha enam on ka andmeid, et vaatamata klassikalise põle-
tiku tunnuste puudumisele kõhres, on põletiku komponent OA kujunemise 
puhul oluline. Nii kondrotsüüdid kui ka sünoviaalkoe rakud on võimsad põle-
tiku mediaatorite allikad (Attur et al., 2002; Loeser, 2008). Sünoviiti esineb 
rohkem kui pooltel põlve OA (POA) haigetest ja seda peetakse üheks faktoriks, 
mis seostub nii haiguse sümptomite ja progressiooniga kui ka võimendab kõhre 
lammutamist (Sellam et al., 2010). 
OA on klassikaline multifaktoriaalne ehk komplekshaigus, mille kujune-
misel on oluline roll nii väliskeskkonna faktoritel kui geneetilisel eelsoodu-
musel (Goldring et al., 2007). Kaksikute uuringute andmetel on POA päritavus 
naistel vähemalt 40% (Spector et al., 1996). Geneetilised faktorid võivad mõju-
tada OA kulgu ja raskust, kuid samuti ka teisi OA riskifaktoreid nagu ülekaal, 
luustiku kuju ja sünoviit (Valdes et al., 2011a). Nagu teiste komplekshaiguste 
puhul, on POA kulgu mõjustavad geenid väikese efektiga ja etniliste erine-
vustega, mistõttu nende kindlakstegemine ei ole lihtne (Reynard et al., 2012; 
Valdes et al., 2011a). POA kandidaatgeenidena on nimetatud kokku üle 80 
geeni, sealhulgas mitmeid liigeskõhre metabolismi anaboolselt ja kataboolselt 
mõjutavaid geene (Chapman et al., 2012). Geneetiliste uuringute eesmärgiks on 
esiteks, geneetiliste seoste kaudu haiguse patogeneetiliste radade leidmine, mida 
tulevikus oleks võimalik potentsiaalselt mõjutada medikamentidega. Teiseks, 
haiguse riski geno- ja haplotüüpide identifitseerimine (van Meurs et al., 2012). 
POA kandidaatgeenidest väärivad tähelepanu ADAM12 (desintegriin ja metall-
opeptidaasi domään 12) ja CILP (kõhre keskmise kihi proteiin) geenid (Valdes 
et al. 2004), mille seost OA-ga on suhteliselt vähe uuritud. Mõlemas geenis on 
kirjeldatud riskialleele, mis on seotud POA esinemise ja progressiooniga UK 
kohordis (Valdes et al., 2004; Valdes et al., 2006). Eesti populatsioonis nende 
kahe geeni seost põlve OA-ga siiani ei ole uuritud. Samas on mõlemal geenil 
potentsiaali saada tulevase POA ravi sihtmärkideks. Selleks aga on vaja 
selgitada haiguse patogeneetilisi radasid üksikasjalikumalt, s.t näidata kandi-





Käesoleva uuringu eesmärgiks oli uurida ADAM12 ja CILP geenide seotust 
põlve OA patogeneesi teatud aspektidega DNA, mRNA ning valgu tasemel 
Eesti populatsioonis. 
Spetsiifilised eesmärgid: 
1. Hinnata ADAM12 (rs3740199, rs1871054, rs1278279, rs1044122) ja CILP 
(rs1561888) geenide ühenukleotiidsete polümorfismide (SNP-de) riski POA 
tekkes Eesti populatsiooni kohordis. 
2. Analüüsida veres mõõdetava ADAM12 valgu kontsentratsiooni seoseid POA 
peamiste radioloogilise tunnustega ja teiste OA biomarkeritega.  
3. Uurida ADAM12 ja CILP seoses sünoviidi ning radioloogilise POA-ga, 
määrates RNA ekspressiooni POA liigese sünoviaalmembraanis ning leides 
nende näitajate seoseid sünoviidi histoloogiliste tunnustega.  
4. Selgitada ADAM12 ja CILP1 valgu võimaliku produktsiooniallikat süno-
viaalmembraanis ning analüüsida seost valgu ja mRNA ekspressiooni vahel. 
 
Uuritavate grupid ja metoodika 
Uurimus hõlmas kaht erinevat uuritavate gruppi–populatsioonil baseeruv kohort 
Lõuna-Eestist (N=437, keskmine vanus 45,2 a., 302 naist ja 135 meest) ning 
artroskoopiliselt ravitud patsientide grupp (N=91, keskmine vanus 47,4 a., 49 
naist ja 42 meest). Artroskoopia grupis koguti kõhre ja sünoviaalbiopsia 
proovitükke RNA eraldamiseks ja histoloogilise sünoviidi hindamiseks 44 
haigel (keskmine vanus 46,7 a., 24 naist ja 20 meest). Kõik uuritavad andsid 
vereproovi DNA eraldamiseks ning vere ja uriiniproovi biomarkerite 
määramiseks.  
DNA eraldati vereproovidest soolamise või fenool-kloroform metoodikaga. 
SNP-d ADAM12 geenis (rs3740199, rs1871054, rs1278279, rs1044122) ja CILP 
geenis (rs1561888) määrati TaqMan® SNP genotüpiseerimise meetodiga ja 
restriktsiooni meetodiga. 
ADAM12-S valku määrati seerumist kokku 276 isikul (185 populatsiooni 
grupis ja 91 artroskoopia grupis), kasutades kommertsiaalset reaktiivide 
komplekti (kitti) DELFIA/AutoDELFIA® ADAM12 (Perkin Elmer Life and 
Analytical Sciences). Kõhre ja sünoviaalmembraani biopsiatest eraldati RNA, 
kasutades Qiageni kommertsiaalseid kitte Rneasy® Mini kit või 
Rneasy® FibrousTissue. Kõhre proovidest eraldatud RNA kvaliteet osutus eda-
siseks uuringuteks ebapiisavaks. ADAM12 ja CILP mRNA ekspressioon määrati 
kvantitatiivse PCR abil kasutades TaqMan® sonde. 
Sünoviidi histoloogiliste tunnuste hindamiseks värviti biopsiatükkidest 
valmistatud koelõigud hematoksüliin-eosiini ja van Gieson meetodil. Sünoovia 
preparaatides hinnati 6 erinevat parameetrit: (1) epiteelirakkude proliferatsiooni, 
(2) infiltreeritust lümfotsüütide ja plasmarakkudega, (3) pindmisi fibriini 
ladestusi, (4) hüpereemiat, (5) fibroosi ja (6) perivaskulaarset turset. Kuue 
tunnuse skooride summeerimisega saadi histoloogilise sünoviidi aste (0−3). 
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ADAM12 ja CILP1 valgu ekspressiooni sünoviaalmembraanis hinnati immuno-
histokeemilise värvimise teel. 
Andmete statistilistel töötlemisel kasutati vabavara R. Geeni polümorfismide 
seoseid POA-ga uuriti logistilise regressiooni mudelite abil, kus lisateguritena 
võeti arvesse uuritavate vanus, sugu ja kehamassi indeks. Mitmiktestimise 
korrektsiooniks valiti Benjamini-Yekutieli meetod. 
Haplotüüpide geneetilise riski hindamiseks kasutati tarkvara paketti 
„haplo.stats”. Valgu ja mRNA ekspressiooni seost POA tunnustega hinnati 
mitteparameetriliste meetoditega (Spearmani astakkorrelatsioon, Wilcoxoni 
test) ja mitmikkorrektsiooniks kasutati permutatsiooni testi või Bonferroni 
korrektsiooni. 
Käesolev uurimus on osa suurest kompleksuuringust, milles osalenud 
patsientidel oli röntgenülesvõtteid põlveliigestest hinnatud Nagaosa-Doherty 
süsteemi järgi (Nagaosa et al., 2000), s.t. eraldi osteofüütide esinemist ja 
liigespilu kitsenemist. Samuti oli määratud luu-kõhrekoe biomarkerid u-CTX-II 
(II tüüpi kollageeni C-terminaalse telopeptiidi fragmendid uriinis), s-PINP 
(I tüüpi prokollageeni amino-terminaalne propeptiid seerumis) ning s-CTX-I 
(I tüüpi kollageeni C-terminaalse telopeptiid), et hinnata nende kudede sünteesi 
ja lammutamise intensiivsust.  
 
Tulemused 
1. Eesti kohordis oli naistel varajase radioloogilise POA risk seotud ADAM12 
geeni SNP-ga rs1044122 (OR 1,63, 95%CI 1,12−2,37; cor. p=0,038) ja 
meestel hilise POA risk SNP-ga rs1871054 (OR 3,82, 95%CI 1,36−10,73; 
cor. p=0,023). 
2. Radioloogilistest tunnustest määrasid ADAM12 geeni variandid ainult 
osteofüütide tekke riski (OR 1,57; p=0,038 rs1044122 (T alleel) ning OR 
3,03; p=0,038 rs1871054 (C alleel) jaoks), kusjuures osteofütoosi riskiga 
oli samuti seotud kahte riskialleeli sisaldav haplotüüp (p=0,014). 
3. ADAM12-S valgu kontsentratsioon seerumis oli kõrgem väljendunud 
radioloogilise POA-ga (aste 2−3) isikutel võrreldes isikutega, kelle puudu-
sid POA radioloogilised tunnused tibiofemoraalses (p=0,0015) ning 
patellofemoraalses liigestes (p=0,0004). Sarnaselt geeniuuringuga, 
ADAM12-S valgu väärtused korreleerusid ainult osteofüütide astmega 
(p=0,003). 
4. Esines seos ADAM12-S ja kõhre lammutamise marker u-CTX-II vahel 
naiste grupis (ρ=0,213; p=0,019). 
5. ADAM12 mRNA ekspresseerus kõikides uuritud sünoviaalbiopsia proovi-
des ja immunohistokeemilise värvimisega kinnitus ka ADAM12 valgu 
süntees sünoovias. 
6. ADAM12 mRNA ekspressioon sünoviaalses membraanis korreleerus histo-
loogilise sünoviidi astmega (ρ=0,28; p=0,039). 
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7. Sünoviiti iseloomustavatest tunnustest esines seos sünoviaalse fibroosi ja 
ADAM12 mRNA mõlema vormi ekspressiooni vahel (ADAM12-L ρ=0,30; 
p=0,028 ning ADAM12-S ρ=0,33; p=0,029 puhul). 
8. CILP mRNA ja vastav valk ekspresseerusid enamikes uuritud sünoovia 
proovides. 
9. Immuunhistokeemiline uuring: CILP1-1 antikehad värvisid sünoviaalkoe 
veresoonte adventiitsia ja meedia kihte ning makrofaagide- ja fibroblastide-
taolisi sünoviotsüüte. Immunoreaktiivsust CILP1-2 antikehaga sünoviaal-
ses membraanis ei leitud. 
10. Kui patsientidel oli liigespilu ilmsesti kitsenenud (röntgenoloogiline aste 
2−3), oli CILP mRNA sünoviaalne ekspressioon oluliselt madalam võrrel-
des POA radioloogiliste tunnusteta isikutega (p=0,0006). Antud seos esines 
ainult meeste grupis (p=0,004). 
11. Sarnaselt ADAM12 geeniga, leiti korrelatsioon CILP mRNA sünoviaalne 
ekspressiooni ning sünoovia fibroosi raskusastmega (ρ=0,31; p=0,026). 
 
Järeldused 
1. Käesolev uurimus näitab esmakordselt olulisi seoseid põlve OA ja 
ADAM12 vahel nii geeni (DNA, mRNA) kui ka valgu tasemel. 
2. Kahte erinevasse haplobloki kuuluvad ADAM12 SNP-d seostusid radio-
loogilise POA riskiga: rs1044122 seostus algava osteofütoosiga (aste 1) 
naistel ja rs1871054 väljendunud osteofütoosiga (aste 2−3) meestel. See 
viitab võimalikule soo-spetsiifilisele ADAM12 rollile osteofüütide for-
meerumisel haiguse varajases või kaugelearenenud staadiumis. 
3. Kaugelearenenud POA-le (aste 2−3) on iseloomulik sekreteeritud 
ADAM12-S kõrgenenud kontsentratsioon vereseerumis: 
o mis viitab võimalusele, et ADAM12-S moduleerib kondrotsüütide pro-
liferatsiooni ning soodustab osteofüütide arengut eeldatavasti insuliini-
sarnase kasvufaktori kättesaadavuse regulatsiooni kaudu. 
o leitud korrelatsioon ADAM12-S valgu ja kõhre lammutamise markeri 
u-CTX-II vahel lubab oletada, et ADAM12-S katalüütiline aktiivsus 
võib soodustada ka II tüüpi kollageeni lõhustamist. 
4. ADAM12 mRNA ja valk sünoviaalses koes olid üleekspresseeritud süno-
viidiga patsientidel, selgemini oli üleekspressioon väljendunud fibroosi 
faasis. See muutus viitab ADAM12 võimalikule osalemisele koe fibro-
seerumisel, mis võiks toimuda TGF-β signaalraja moduleerimise kaudu. 
5. Uut OA biomarkerit CILP1, mida seostatakse kõhrega ja selle meta-
bolismiga, leiti sünoviaalses koes nii mRNA kui ka valgu tasemel. Leid 
osutab võimalusele, et sünoviaalmembraan võib olla täiendavaks CILP1 
produktsiooni allikaks sünoviaalsetes liigestes. Histokeemilise uuringuga 
täpsustati, et CILP1 võivad toota sünoovia veresoonte silelihasrakud ning 
makrofaagi- ja fibroblasti-taolised sünoviotsüüdid. 
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6. Sarnaselt ADAM12-ga, leiti CILP mRNA üleekspressioon fibrootilistes 
sünoviaalmembraani proovides. See viitab CILP1 võimalikule osalemisele 
põletikujärgse fibroosi formeerumisel, arvatavasti TGF-β aktivatsiooni 
kaudu. 
7. Erinevalt ADAM12-st oli CILP mRNA sünoviaalne ekspressioon meestel 
oluliselt madalam kõhre kaugelearenenud degradatsioon faasis (patsientide 
põlve liigespilu ahenemine astmes 2−3), viidates CILP sünoviaalse pro-
duktsiooni vähenemisele haiguse hilises faasis. 
 
Käesolev uurimus näitab olulisi seoseid põlve OA ja ADAM12 vahel nii geeni 
(DNA, mRNA) kui ka valgu tasemel. Tulemused viitavad võimalusele, et 
ADAM12 osaleb liigeskudede remodelleerumisprotsessides−osteofüütide tekkes 
ja sünoovia fibroseerumises. Sarnaselt ADAM12-ga, leiti CILP seos osteo-
artriitiliste protsessidega liigeses. Seni on seda valku seostatud liigeskõhre 
metabolismiga, kuid käesolevas töös näidatakse CILP ekspressiooni ka liigese 
sünoviaalkoes. Uuring demonstreerib mõlema geeni sarnast käitumist OA 
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